,sentence_text,e1,e2,relation_type,normalized_sentence
0,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,Ethanol,abacavir,mechanism,DRUG decreases_be elimination_be OTHER_DRUG causing_af increase_af overall_af exposure_af ._af The_af addition_af methadone_af clinically_af significant_af effect_af pharmacokinetic_af properties_af OTHER_DRUG ._af
1,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",methadone,ZIAGEN,mechanism,"In_bf study_bf 11_bf HIV-infected_bf patients_bf receiving_bf methadone-maintenance_bf therapy_bf (40_bf mg_bf 90_bf mg_bf daily)_bf 600_bf mg_bf OTHER_DRUG twice_be daily_be (twice_be currently_be recommended_be dose)_be ,_be oral_be DRUG clearance_af increased_af 22%_af (90%_af CI_af 6%_af 42%)_af ._af"
2,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,cholestyramine,ezetimibe,mechanism,Cholestyramine:_bf Concomitant_bf DRUG administration_be decreased_be mean_be AUC_be total_be OTHER_DRUG approximately_af 55%_af ._af
3,The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. ,ezetimibe,cholestyramine,effect,The_bf incremental_bf LDL-C_bf reduction_bf due_bf adding_bf DRUG OTHER_DRUG may_af reduced_af interaction_af ._af
4,Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. ,ZETIA,fibrates,advise,Co-administration_bf DRUG OTHER_DRUG recommended_af use_af patients_af studied_af ._af
5,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",fenofibrate,ezetimibe,mechanism,"Fenofibrate:_bf In_bf pharmacokinetic_bf study_bf ,_bf concomitant_bf DRUG administration_be increased_be total_be OTHER_DRUG concentrations_af approximately_af 1_af ._af 5-fold_af ._af"
6,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",ezetimibe,cyclosporine,mechanism,"Cyclosporine:_bf The_bf total_bf DRUG level_be increased_be 12-fold_be one_be renal_be transplant_be patient_be receiving_be multiple_be medications_be ,_be including_be OTHER_DRUG ._af"
7,Patients who take both ezetimibe and cyclosporine should be carefully monitored. ,ezetimibe,cyclosporine,advise,Patients_bf take_bf DRUG OTHER_DRUG carefully_af monitored_af ._af
8,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,cimetidine,mebendazole,mechanism,Preliminary_bf evidence_bf suggests_bf DRUG inhibits_be OTHER_DRUG metabolism_af may_af result_af increase_af plasma_af concentrations_af OTHER_DRUG ._af
9,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,antibiotics,ganglion blockers,advise,Patients_bf receiving_bf DRUG sulfonamides_be generally_be treated_be ganglion_be blockers_be ._be
10,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,sulfonamides,ganglion blockers,advise,Patients_bf receiving_bf antibiotics_bf DRUG generally_be treated_be ganglion_be blockers_be ._be
11,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,antihypertensive drugs,effect,"The_bf action_bf DRUG may_be potentiated_be anesthesia_be ,_be antihypertensive_be drugs_be alcohol_be ._be"
12,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,alcohol,effect,"The_bf action_bf DRUG may_be potentiated_be anesthesia_be ,_be antihypertensive_be drugs_be OTHER_DRUG ._af"
13,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,Aminoglutethimide,depo-subQ provera 104,mechanism,DRUG administered_be concomitantly_be depo-subQ_be provera_be 104_be may_be significantly_be decrease_be serum_be concentrations_be MPA_be ._be
14,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,megestrol acetate,indinavir,mechanism,A_bf pharmacokinetic_bf study_bf demonstrated_bf coadministration_bf megestrol_bf acetate_bf OTHER_DRUG results_be significant_be decrease_be pharmacokinetic_be parameters_be (~36%_be Cmax_be ~28%_be AUC)_be OTHER_DRUG ._af
15,Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. ,indinavir,megestrol acetate,advise,Administration_bf higher_bf dose_bf DRUG considered_be coadministering_be megestrol_be acetate_be ._be
16,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,aspirin,int,"DRUG may_be interact_be following_be drugs:_be OTHER_DRUG NSAIDs_af (may_af lower_af DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
17,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,NSAIDs,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be OTHER_DRUG (may_af lower_af DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
18,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,fluvoxamine,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af OTHER_DRUG (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
19,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,beta blockers,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
20,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,fluoxetine,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af OTHER_DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
21,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,progestin,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
22,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,benzodiazepenes,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
23,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,corticosteroids,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
24,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,effect,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
25,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,effect,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
26,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors,effect,ACE_bf inhibitors_bf Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be angiotensin-converting_be enzyme_be (ACE)_be inhibitors_be ._be
27,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. ,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
28,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,aspirin,meloxicam,mechanism,Aspirin:_bf Concomitant_bf administration_bf DRUG (1000_be mg_be TID)_be healthy_be volunteers_be tended_be increase_be AUC_be (10%)_be Cmax_be (24%)_be OTHER_DRUG ._af
29,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",NSAIDs,aspirin,advise,"however_bf ,_bf DRUG ,_be concomitant_be administration_be meloxicam_be OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
30,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",meloxicam,aspirin,advise,"however_bf ,_bf NSAIDs_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
31,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",aspirin,MOBIC,effect,"Concomitant_bf administration_bf low-dose_bf DRUG OTHER_DRUG may_af result_af increased_af rate_af GI_af ulceration_af complications_af ,_af compared_af use_af OTHER_DRUG alone_af ._af"
32,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,cholestyramine,meloxicam,mechanism,Cholestyramine:_bf Pretreatment_bf four_bf days_bf DRUG significantly_be increased_be clearance_be OTHER_DRUG 50%_af ._af
33,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,furosemide,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazide_af diuretics_af patients_af ._af"
34,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,thiazide diuretics,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be thiazide_be diuretics_be patients_be ._be"
35,"Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",furosemide,MOBIC,advise,"Nevertheless_bf ,_bf concomitant_bf therapy_bf DRUG OTHER_DRUG ,_af patients_af observed_af closely_af signs_af declining_af renal_af function_af ,_af well_af assure_af diuretic_af efficacy_af ._af"
36,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",NSAIDs,lithium,mechanism,"Lithium:_bf In_bf clinical_bf trials_bf ,_bf DRUG produced_be elevation_be plasma_be OTHER_DRUG levels_af reduction_af renal_af OTHER_DRUG clearance_af ._af"
37,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,meloxicam,mechanism,"In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf pre-dose_bf DRUG concentration_be AUC_be increased_be 21%_be subjects_be receiving_be DRUG doses_af ranging_af 804_af 1072_af mg_af BID_af OTHER_DRUG 15_af mg_af QD_af compared_af subjects_af receiving_af DRUG alone_af ._af"
38,Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. ,lithium,MOBIC,advise,Patients_bf DRUG treatment_be closely_be monitored_be OTHER_DRUG introduced_af withdrawn_af ._af
39,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",MOBIC,warfarin,advise,"Warfarin:_bf Anticoagulant_bf activity_bf monitored_bf ,_bf particularly_bf first_bf days_bf initiating_bf changing_bf DRUG therapy_be patients_be receiving_be OTHER_DRUG similar_af agents_af ,_af since_af patients_af increased_af risk_af bleeding_af ._af"
40,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,advise,Caution_bf used_bf administering_bf DRUG OTHER_DRUG since_af patients_af OTHER_DRUG may_af experience_af changes_af INR_af increased_af risk_af bleeding_af complications_af new_af medication_af introduced_af ._af
41,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,Nalidixic acid,melphalan,effect,DRUG_bf INTERACTIONS_bf There_bf known_bf drug/drug_bf interactions_bf oral_bf ALKERAN_bf Vaccinations_bf live_bf organism_bf vaccines_bf recommended_bf immunocompromised_bf individuals_bf Nalidixic_bf acid_bf together_bf high-dose_bf intravenous_bf OTHER_DRUG caused_be deaths_be children_be due_be haemorrhagic_be enterocolitis_be ._be
42,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease,melphalan,cyclosporin,effect,Impaired_bf renal_bf function_bf described_bf bone_bf marrow_bf transplant_bf patients_bf conditioned_bf high-dose_bf intravenous_bf DRUG subsequently_be received_be OTHER_DRUG prevent_af graft-versus-host_af disease_af
43,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,amantadine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf OTHER_DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
44,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antiarrhythmic agents of class I,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
45,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,quinidine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
46,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antihistamines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf OTHER_DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
47,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antipsychotic agents,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
48,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,phenothiazines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
49,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,benzodiazepines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf OTHER_DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
50,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,MAO inhibitors,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
51,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,narcotic analgesics,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
52,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,meperidine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
53,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrates,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
54,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrites,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
55,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,sympathomimetic agents,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
56,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,tricyclic antidepressants,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
57,Anticholinergics antagonize the effects of antiglaucoma agents. ,Anticholinergics,antiglaucoma agents,effect,DRUG antagonize_be effects_be antiglaucoma_be agents_be ._be
58,Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. ,Anticholinergic drugs,corticosteroids,effect,Anticholinergic_bf drugs_bf presence_bf increased_bf intraocular_bf pressure_bf may_bf hazardous_bf taken_bf concurrently_bf agents_bf OTHER_DRUG ._be
59,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; ",Anticholinergic agents,digoxin,mechanism,"Anticholinergic_bf agents_bf may_bf affect_bf gastrointestinal_bf absorption_bf various_bf drugs_bf ,_bf slowly_bf dissolving_bf dosage_bf forms_bf digoxin;_bf"
60,"Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. ",Anticholinergic drugs,metoclopramide,effect,"Anticholinergic_bf drugs_bf may_bf antagonize_bf effects_bf drugs_bf alter_bf gastrointestinal_bf motility_bf ,_bf OTHER_DRUG ._be"
61,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. ",antacids,anticholinergic agents,mechanism,"Because_bf DRUG may_be interfere_be absorption_be anticholinergic_be agents_be ,_be simultaneous_be use_be drugs_be avoided_be ._be"
62,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,alcohol,effect,"DRUG may_be enhance_be effects_be OTHER_DRUG ,_af barbiturates_af CNS_af depressants_af ._af"
63,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,barbiturates,effect,"DRUG may_be enhance_be effects_be alcohol_be ,_be OTHER_DRUG CNS_af depressants_af ._af"
64,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,CNS depressants,effect,"DRUG may_be enhance_be effects_be alcohol_be ,_be barbiturates_be CNS_be depressants_be ._be"
65,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,methazolamide,advise,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf DRUG OTHER_DRUG concomitantly_af ,_af anorexia_af ,_af tachypnea_af ,_af lethargy_af ,_af coma_af death_af reported_af concomitant_af use_af high-dose_af DRUG carbonic_af anhydrase_af inhibitors_af ._af"
66,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,carbonic anhydrase inhibitors,effect,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf DRUG methazolamide_be concomitantly_be ,_be anorexia_be ,_be tachypnea_be ,_be lethargy_be ,_be coma_be death_be reported_be concomitant_be use_be high-dose_be DRUG carbonic_af anhydrase_af inhibitors_af ._af"
67,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,anticoagulants,methimazole,effect,DRUG (oral):_be The_be activity_be oral_be DRUG may_af potentiated_af anti-vitamin-K_af activity_af attributed_af OTHER_DRUG ._af
68,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",opioids,levomepromazine,effect,"Dosages_bf concomitantly_bf administered_bf DRUG reduced_be approximately_be half_be ,_be OTHER_DRUG amplifies_af therapeutic_af actions_af side-effects_af DRUG ._af"
69,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",levomepromazine,opioids,effect,"Dosages_bf concomitantly_bf administered_bf OTHER_DRUG reduced_be approximately_be half_be ,_be DRUG amplifies_af therapeutic_af actions_af side-effects_af OTHER_DRUG ._af"
70,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,benzodiazepines,effect,Additive_bf sedative_bf effects_bf confusional_bf states_bf may_bf emerge_bf DRUG given_be OTHER_DRUG barbiturates_af ._af
71,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,barbiturates,effect,Additive_bf sedative_bf effects_bf confusional_bf states_bf may_bf emerge_bf DRUG given_be benzodiazepines_be OTHER_DRUG ._af
72,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,anticholinergic drugs,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
73,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,tricyclic antidepressants,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
74,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,antiparkinsonian-agents,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
75,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,Caffeine,levomepromazine,effect,DRUG and/or_be stimulantes_be ephedrine/amphetamine_be type_be may_be counteract_be specific_be actions_be OTHER_DRUG ._af
76,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,ephedrine,levomepromazine,effect,Caffeine_bf and/or_bf stimulantes_bf ephedrine/amphetamine_bf type_bf may_bf counteract_bf specific_bf actions_bf OTHER_DRUG ._be
77,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,amphetamine,levomepromazine,effect,Caffeine_bf and/or_bf stimulantes_bf ephedrine/amphetamine_bf type_bf may_bf counteract_bf specific_bf actions_bf OTHER_DRUG ._be
78,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,antiepileptic drugs,advise,"Since_bf DRUG (methsuximide)_be may_be interact_be concurrently_be administered_be antiepileptic_be drugs_be ,_be periodic_be serum_be level_be determinations_be drugs_be may_be necessary_be (eg_be methsuximide_be may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
79,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,antiepileptic drugs,advise,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
80,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenytoin,mechanism,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be OTHER_DRUG phenobarbital)_af ._af"
81,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenobarbital,mechanism,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
82,Thiazides may decrease arterial responsiveness to norepinephrine. ,Thiazides,norepinephrine,effect,DRUG may_be decrease_be arterial_be responsiveness_be OTHER_DRUG ._af
83,Thiazide drugs may increase the responsiveness of tubocurarine. ,Thiazide drugs,tubocurarine,effect,Thiazide_bf drugs_bf may_bf increase_bf responsiveness_bf OTHER_DRUG ._be
84,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",Lithium,thiazides,mechanism,"DRUG renal_be clearance_be reduced_be OTHER_DRUG ,_af increasing_af risk_af DRUG toxicity_af ._af"
85,Thiazides may add to or potentiate the action of other antihypertensive drugs. ,Thiazides,antihypertensive drugs,effect,DRUG may_be add_be potentiate_be action_be antihypertensive_be drugs_be ._be
86,"When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. ",methyldopa,antihypertensive drugs,effect,"When_bf DRUG used_be antihypertensive_be drugs_be ,_be potentiation_be antihypertensive_be effect_be may_be occur_be ._be"
87,Patients may require reduced doses of anesthetics when on methyldopa. ,anesthetics,methyldopa,advise,Patients_bf may_bf require_bf reduced_bf doses_bf DRUG OTHER_DRUG ._af
88,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,methyldopa,lithium,advise,When_bf DRUG OTHER_DRUG given_af concomitantly_af patient_af carefully_af monitored_af symptoms_af OTHER_DRUG toxicity_af ._af
89,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous sulfate,mechanism,Several_bf studies_bf demonstrate_bf decrease_bf bioavailability_bf DRUG ingested_be ferrous_be sulfate_be ferrous_be gluconate_be ._be
90,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous gluconate,mechanism,Several_bf studies_bf demonstrate_bf decrease_bf bioavailability_bf DRUG ingested_be ferrous_be sulfate_be ferrous_be gluconate_be ._be
91,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous sulfate,advise,Coadministration_bf DRUG ferrous_be sulfate_be ferrous_be gluconate_be recommended_be ._be
92,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous gluconate,advise,Coadministration_bf DRUG ferrous_be sulfate_be ferrous_be gluconate_be recommended_be ._be
93,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,vasoconstrictors,advise,Caution_bf exercised_bf DRUG (methylergonovine_be maleate)_be used_be concurrently_be OTHER_DRUG ergot_af alkaloids_af ._af
94,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,ergot alkaloids,advise,Caution_bf exercised_bf DRUG (methylergonovine_be maleate)_be used_be concurrently_be vasoconstrictors_be ergot_be alkaloids_be ._be
95,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,methylergonovine maleate,vasoconstrictors,advise,Caution_bf exercised_bf Methergine_bf (methylergonovine_bf maleate)_bf used_bf concurrently_bf OTHER_DRUG ergot_be alkaloids_be ._be
96,Ritalin may decrease the hypotensive effect of guanethidine. ,Ritalin,guanethidine,effect,DRUG may_be decrease_be hypotensive_be effect_be OTHER_DRUG ._af
97,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,coumarin anticoagulants,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
98,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,anticonvulsants,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be OTHER_DRUG (phenobarbital_af ,_af diphenylhydantoin_af ,_af primidone)_af ,_af phenylbutazone_af ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
99,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenobarbital,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
100,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,diphenylhydantoin,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be OTHER_DRUG ,_af primidone)_af ,_af phenylbutazone_af ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
101,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,primidone,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
102,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenylbutazone,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be OTHER_DRUG ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
103,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,tricyclic drugs,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
104,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,imipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
105,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,clomipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be OTHER_DRUG ,_af desipramine)_af ._af"
106,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,desipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
107,Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; ,cyclosporin,methylprednisolone,mechanism,Mutual_bf inhibition_bf metabolism_bf occurs_bf concurrent_bf use_bf DRUG methylprednisolone;_be
108,convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. ,methylprednisolone,cyclosporin,effect,convulsions_bf reported_bf concurrent_bf use_bf DRUG OTHER_DRUG ._af
109,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
110,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
111,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
112,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
113,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
114,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
115,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,troleandomycin,methylprednisolone,mechanism,Drugs_bf DRUG ketoconazole_be may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
116,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,ketoconazole,methylprednisolone,mechanism,Drugs_bf troleandomycin_bf DRUG may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
117,Methylprednisolone may increase the clearance of chronic high dose aspirin. ,Methylprednisolone,aspirin,mechanism,DRUG may_be increase_be clearance_be chronic_be high_be dose_be OTHER_DRUG ._af
118,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,salicylate,methylprednisolone,effect,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af OTHER_DRUG withdrawn_af ._af
119,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG patients_af suffering_af hypoprothrombinemia_af ._af
120,There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. ,anticoagulant,corticosteroids,effect,There_bf reports_bf enhanced_bf well_bf diminished_bf effects_bf DRUG given_be concurrently_be OTHER_DRUG ._af
121,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,tricyclic,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
122,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,MAO inhibitors,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
123,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,phenelzine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af linezolid_af ,_af tranylcypromine_af ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
124,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,linezolid,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be OTHER_DRUG ,_af tranylcypromine_af ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
125,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,tranylcypromine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be OTHER_DRUG ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
126,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,isocarboxazid,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be OTHER_DRUG ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
127,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,selegiline,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be OTHER_DRUG ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
128,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,furazolidone,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
129,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,quinidine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be OTHER_DRUG ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
130,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,amantadine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
131,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antihistamines,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
132,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,diphenhydramine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
133,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,anticholinergics,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
134,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,potassium chloride,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
135,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antacids,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
136,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,absorbent-type anti-diarrhea medicines,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
137,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,kaolin,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
138,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,pectin,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
139,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,phenothiazines,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
140,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,chlorpromazine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
141,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,promethazine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
142,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,alcohol,methyprylon,effect,Concurrent_bf use_bf DRUG CNS_be depression-producing_be drugs_be may_be increase_be CNS_be depressant_be effects_be OTHER_DRUG medications_af ._af
143,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,CNS depression-producing drugs,methyprylon,effect,Concurrent_bf use_bf alcohol_bf CNS_bf depression-producing_bf drugs_bf may_bf increase_bf CNS_bf depressant_bf effects_bf OTHER_DRUG medications_be ._be
144,Methysergide may reverse the analgesic activity of narcotic analgesics. ,Methysergide,narcotic analgesics,effect,DRUG may_be reverse_be analgesic_be activity_be narcotic_be analgesics_be ._be
145,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,anticholinergic drugs,effect,The_bf effects_bf DRUG gastrointestinal_be motility_be antagonized_be anticholinergic_be drugs_be narcotic_be analgesics_be ._be
146,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,narcotic analgesics,effect,The_bf effects_bf DRUG gastrointestinal_be motility_be antagonized_be anticholinergic_be drugs_be narcotic_be analgesics_be ._be
147,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,alcohol,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be OTHER_DRUG ,_af sedatives_af ,_af hypnotics_af ,_af narcotics_af ,_af tranquilizers_af ._af"
148,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,sedatives,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be OTHER_DRUG ,_af hypnotics_af ,_af narcotics_af ,_af tranquilizers_af ._af"
149,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,hypnotics,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be OTHER_DRUG ,_af narcotics_af ,_af tranquilizers_af ._af"
150,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,narcotics,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be OTHER_DRUG ,_af tranquilizers_af ._af"
151,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,tranquilizers,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be narcotics_be ,_be OTHER_DRUG ._af"
152,"The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. ",metoclopramide,monoamine oxi-dase inhibitors,advise,"The_bf finding_bf DRUG releases_be catecholamines_be patients_be essential_be hypertension_be suggests_be used_be cautiously_be ,_be ,_be patients_be receiving_be monoamine_be oxi-dase_be inhibitors_be ._be"
153,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,metoclopramide,mechanism,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf OTHER_DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be acetaminophen_be ,_be tetracycline_be ,_be levodopa_be ,_be ethanol_be ,_be cyclosporine)_be ._be"
154,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,acetaminophen,mechanism,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracycline_af ,_af levodopa_af ,_af ethanol_af ,_af cyclosporine)_af ._af"
155,"Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.",metoclopramide,insulin,advise,"Because_bf action_bf DRUG influence_be delivery_be food_be intestines_be thus_be rate_be absorption_be ,_be OTHER_DRUG dosage_af timing_af dosage_af may_af require_af adjustment_af ._af"
156,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,coumarin,effect,"Oral_bf DRUG reported_be potentiate_be anticoagulant_be effect_be OTHER_DRUG warfarin_af ,_af resulting_af prolongation_af prothrombin_af time_af ._af"
157,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,warfarin,effect,"Oral_bf DRUG reported_be potentiate_be anticoagulant_be effect_be coumarin_be OTHER_DRUG ,_af resulting_af prolongation_af prothrombin_af time_af ._af"
158,The metabolism of Metopirone is accelerated by phenytoin; ,Metopirone,phenytoin,mechanism,The_bf metabolism_bf DRUG accelerated_be phenytoin;_be
159,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,mechanism,DRUG inhibits_be glucuronidation_be OTHER_DRUG could_af possibly_af potentiate_af OTHER_DRUG toxicity_af ._af
160,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,effect,DRUG inhibits_be glucuronidation_be OTHER_DRUG could_af possibly_af potentiate_af OTHER_DRUG toxicity_af ._af
161,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,phenothiazines,advise,Caution_bf observed_bf administering_bf DRUG patients_be receiving_be OTHER_DRUG haloperidol_af extrapyramidal_af effects_af drugs_af expected_af potentiated_af inhibition_af catecholamine_af synthesis_af ._af
162,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,haloperidol,advise,Caution_bf observed_bf administering_bf DRUG patients_be receiving_be phenothiazines_be OTHER_DRUG extrapyramidal_af effects_af drugs_af expected_af potentiated_af inhibition_af catecholamine_af synthesis_af ._af
163,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,alcohol,effect,Concurrent_bf use_bf DRUG OTHER_DRUG CNS_af depressants_af increase_af sedative_af effects_af ._af
164,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,CNS depressants,effect,Concurrent_bf use_bf DRUG alcohol_be CNS_be depressants_be increase_be sedative_be effects_be ._be
165,"In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. ",mexiletine,fluvoxamine,mechanism,"In_bf formal_bf ,_bf single-dose_bf interaction_bf study_bf (n_bf =_bf 6_bf males)_bf clearance_bf DRUG decreased_be 38%_be following_be coadministration_be OTHER_DRUG ,_af inhibitor_af CYP1A2_af ._af"
166,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenytoin,Mexitil,mechanism,"When_bf DRUG hepatic_be enzyme_be inducers_be rifampin_be phenobarbital_be taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
167,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",rifampin,Mexitil,mechanism,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf DRUG phenobarbital_be taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
168,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenobarbital,Mexitil,mechanism,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf rifampin_bf DRUG taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
169,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",cimetidine,Mexitil,mechanism,"Concurrent_bf administration_bf DRUG OTHER_DRUG reported_af increase_af ,_af decrease_af ,_af leave_af unchanged_af OTHER_DRUG plasma_af levels;_af"
170,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",magnesium-aluminum hydroxide,digoxin,mechanism,"Mexitil_bf alter_bf serum_bf OTHER_DRUG levels_be magnesium-aluminum_be hydroxide_be ,_be used_be treat_be gastrointestinal_be symptoms_be due_be Mexitil_be ,_be reported_be lower_be serum_be OTHER_DRUG levels_af ._af"
171,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,Mexitil,theophylline,mechanism,Concurrent_bf use_bf DRUG OTHER_DRUG may_af lead_af increased_af plasma_af OTHER_DRUG levels_af ._af
172,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,Mexitil,mechanism,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf OTHER_DRUG ._be DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af OTHER_DRUG ._af If_af OTHER_DRUG DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af OTHER_DRUG dose_af changed_af ._af"
173,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,advise,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
174,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .",caffeine,Mexitil,mechanism,"Additionally_bf ,_bf one_bf controlled_bf study_bf five_bf normal_bf subjects_bf seven_bf patients_bf ,_bf clearance_bf DRUG decreased_be 50%_be following_be administration_be OTHER_DRUG ._af"
175,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,terfenadine,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be OTHER_DRUG ,_af astemizole_af ,_af cisapride_af ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
176,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,astemizole,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be OTHER_DRUG ,_af cisapride_af ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
177,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cisapride,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be OTHER_DRUG ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
178,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cyclosporine,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be cisapride_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ._af"
179,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,tricyclic antidepressants,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be cisapride_be ,_be cyclosporine_be ,_be tricyclic_be antidepressants_be ._be"
180,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,Sirolimus,MYCAMINE,mechanism,DRUG AUC_be increased_be 21%_be effect_be Cmax_be presence_be steady-state_be OTHER_DRUG compared_af DRUG alone_af ._af
181,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",Nifedipine,MYCAMINE,mechanism,"DRUG AUC_be Cmax_be increased_be 18%_be 42%_be ,_be respectively_be ,_be presence_be steady-state_be OTHER_DRUG compared_af DRUG alone_af ._af"
182,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,MYCAMINE,advise,Patients_bf receiving_bf DRUG nifedipine_be combination_be OTHER_DRUG monitored_af DRUG nifedipine_af toxicity_af DRUG nifedipine_af dosage_af reduced_af necessary_af ._af
183,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,MYCAMINE,advise,Patients_bf receiving_bf sirolimus_bf DRUG combination_be OTHER_DRUG monitored_af sirolimus_af DRUG toxicity_af sirolimus_af DRUG dosage_af reduced_af necessary_af ._af
184,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,azole antimycotics,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
185,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,protease inhibitors,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
186,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,calcium channel antagonists,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
187,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,macrolide antibiotics,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
188,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,midazolam,mechanism,"Drugs_bf DRUG ,_be diltiazem_be ,_be verapamil_be ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
189,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf DRUG ,_be verapamil_be ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
190,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",verapamil,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf DRUG ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
191,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",ketoconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf DRUG ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
192,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",fluconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf ketoconazole_bf ,_bf DRUG itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
193,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",itraconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf ketoconazole_bf ,_bf fluconazole_bf DRUG shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
194,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",ritonavir,midazolam,mechanism,"Although_bf studied_bf ,_bf potent_bf cytochrome_bf P450_bf 3A4_bf inhibitors_bf DRUG nelfinavir_be may_be cause_be intense_be prolonged_be sedation_be respiratory_be depression_be due_be decrease_be plasma_be clearance_be OTHER_DRUG ._af"
195,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",nelfinavir,midazolam,mechanism,"Although_bf studied_bf ,_bf potent_bf cytochrome_bf P450_bf 3A4_bf inhibitors_bf ritonavir_bf DRUG may_be cause_be intense_be prolonged_be sedation_be respiratory_be depression_be due_be decrease_be plasma_be clearance_be OTHER_DRUG ._af"
196,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",rifampin,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf DRUG ,_be carbamazepine_be ,_be phenytoin_be ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
197,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",carbamazepine,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf rifampin_bf ,_bf DRUG ,_be phenytoin_be ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
198,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",phenytoin,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf rifampin_bf ,_bf carbamazepine_bf ,_bf DRUG ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
199,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,narcotics,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf OTHER_DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
200,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,morphine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf OTHER_DRUG ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
201,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,meperidine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf OTHER_DRUG fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
202,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,fentanyl,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf droperidol_bf ._bf"
203,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,propofol,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf OTHER_DRUG ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
204,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,ketamine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf OTHER_DRUG ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
205,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,nitrous oxide,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf droperidol_bf ._bf"
206,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,secobarbital,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf OTHER_DRUG droperidol_be ._be"
207,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,droperidol,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf OTHER_DRUG ._be"
208,"When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. ",ProAmatine,cardiac glycosides,effect,"When_bf administered_bf concomitantly_bf DRUG ,_be cardiac_be glycosides_be may_be enhance_be precipitate_be bradycardia_be ,_be A_be ._be V_be ._be"
209,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pseudoephedrine_be ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
210,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf DRUG ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
211,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf DRUG ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
212,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf DRUG dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
213,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",dihydroergotamine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf phenylpropanolamine_bf dihydroergotamine)_bf may_bf enhance_bf potentiate_bf pressor_bf effects_bf OTHER_DRUG ._be Therefore_be ,_be caution_be used_be OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
214,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
215,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be DRUG ,_af terazosin_af ,_af doxazosin_af ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
216,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be DRUG ,_af doxazosin_af ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
217,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be DRUG ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
218,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,metformin,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be OTHER_DRUG ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
219,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,cimetidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
220,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,ranitidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
221,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,procainamide,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
222,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,triamterene,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
223,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,flecainide,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
224,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,quinidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
225,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",ketoconazole,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
226,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",itraconazole,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be DRUG ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
227,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",erythromycin,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be itraconazole_be ,_be DRUG ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
228,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf DRUG (phenytoin_be ,_be phenobarbital_be ,_be carbamazepine)_be may_be induce_be OTHER_DRUG metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
229,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenytoin,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf OTHER_DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
230,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenobarbital,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf DRUG ,_be carbamazepine)_be may_be induce_be OTHER_DRUG metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
231,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",carbamazepine,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf OTHER_DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
232,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",ZAVESCA,Cerezyme,mechanism,"While_bf co-administration_bf DRUG appeared_be increase_be clearance_be OTHER_DRUG 70%_af ,_af results_af conclusive_af small_af number_af subjects_af studied_af patients_af took_af variable_af doses_af OTHER_DRUG ._af"
233,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,Cerezyme,ZAVESCA,advise,Combination_bf therapy_bf DRUG (imiglucerase)_be OTHER_DRUG indicated_af ._af
234,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,imiglucerase,ZAVESCA,advise,Combination_bf therapy_bf Cerezyme_bf (imiglucerase)_bf OTHER_DRUG indicated_be ._be
235,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",tetracyclines,anticoagulant,advise,"Because_bf DRUG shown_be depress_be plasma_be prothrombin_be activity_be ,_be patients_be OTHER_DRUG therapy_af may_af require_af downward_af adjustment_af OTHER_DRUG dosage_af ._af"
236,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",tetracycline class drugs,penicillin,advise,"Since_bf bacteriostatic_bf drugs_bf may_bf interfere_bf bactericidal_bf action_bf OTHER_DRUG ,_be advisable_be avoid_be giving_be tetracycline_be class_be drugs_be conjunction_be OTHER_DRUG ._af"
237,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,aluminum,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be OTHER_DRUG ,_af calcium_af magnesium_af ,_af iron-containing_af preparations_af ._af"
238,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,calcium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be OTHER_DRUG magnesium_af ,_af iron-containing_af preparations_af ._af"
239,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,magnesium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be OTHER_DRUG ,_af iron-containing_af preparations_af ._af"
240,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,iron,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be magnesium_be ,_be iron-containing_be preparations_be ._be"
241,The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ,tetracycline,methoxyflurane,effect,The_bf concurrent_bf use_bf DRUG OTHER_DRUG reported_af result_af fatal_af renal_af toxicity_af ._af
242,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent_bf use_bf DRUG oral_be OTHER_DRUG may_af render_af oral_af OTHER_DRUG less_af effective_af ._af
243,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",minoxidil,guanethidine,effect,"Interaction_bf Guanethidine:_bf Although_bf DRUG cause_be orthostatic_be hypotension_be ,_be administration_be patients_be already_be receiving_be OTHER_DRUG result_af profound_af orthostatic_af effects_af ._af"
244,If at all possible guanethidine should be discontinued well before minoxidil is begun. ,guanethidine,minoxidil,advise,If_bf possible_bf DRUG discontinued_be well_be OTHER_DRUG begun_af ._af
245,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,alcohol,mirtazapine,mechanism,Alcohol:_bf Concomitant_bf administration_bf DRUG (equivalent_be 60_be g)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 6_af healthy_af male_af subjects_af ._af
246,"However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. ",REMERON,alcohol,effect,"However_bf ,_bf impairment_bf cognitive_bf motor_bf skills_bf produced_bf DRUG shown_be additive_be produced_be OTHER_DRUG ._af"
247,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",alcohol,REMERON SolTab,advise,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG taking_be REMERON_be SolTab_be ._be Diazepam:_be Concomitant_be administration_be diazepam_be (15_be mg)_be minimal_be effect_be plasma_be levels_be mirtazapine_be (15_be mg)_be 12_be healthy_be subjects_be ._be"
248,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",diazepam,mirtazapine,mechanism,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf alcohol_bf taking_bf REMERON_bf SolTab_bf ._bf Diazepam:_bf Concomitant_bf administration_bf DRUG (15_be mg)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 12_af healthy_af subjects_af ._af"
249,"However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. ",REMERON,diazepam,effect,"However_bf ,_bf impairment_bf motor_bf skills_bf produced_bf DRUG shown_be additive_be caused_be OTHER_DRUG ._af"
250,"Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.",diazepam,REMERON SolTab,advise,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG similar_be drugs_be taking_be REMERON_be SolTab_be ._be"
251,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",Mitotane,warfarin,mechanism,"DRUG reported_be accelerate_be metabolism_be OTHER_DRUG mechanism_af hepatic_af microsomal_af enzyme_af induction_af ,_af leading_af increase_af dosage_af requirements_af OTHER_DRUG ._af"
252,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",Mitotane,coumarin-type anticoagulants,advise,"Therefore_bf ,_bf physicians_bf closely_bf monitor_bf patients_bf change_bf anticoagulant_bf dosage_bf requirements_bf administering_bf DRUG patients_be coumarin-type_be anticoagulants_be ._be"
253,Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. ,succinylcholine,nondepolarizing agents,effect,Prior_bf administration_bf DRUG potentiate_be neuromuscular_be blocking_be effects_be nondepolarizing_be agents_be ._be
254,Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. ,succinylcholine,MIVACRON,advise,Evidence_bf spontaneous_bf recovery_bf DRUG observed_be administration_be OTHER_DRUG ._af
255,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,antibiotics,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf OTHER_DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
256,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,aminoglycosides,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
257,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,tetracyclines,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf OTHER_DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
258,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,bacitracin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf OTHER_DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
259,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,polymyxins,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf OTHER_DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
260,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,lincomycin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf OTHER_DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
261,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,clindamycin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf OTHER_DRUG ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
262,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,colistin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf OTHER_DRUG ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
263,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,sodium colistimethate,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf quinidine_bf ._bf"
264,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,magnesium,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf OTHER_DRUG salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
265,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,lithium,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf OTHER_DRUG ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
266,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,anesthetics,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf OTHER_DRUG ,_be procainamide_be ,_be quinidine_be ._be"
267,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,procainamide,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf OTHER_DRUG ,_be quinidine_be ._be"
268,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,quinidine,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf OTHER_DRUG ._be"
269,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,antibiotics,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be OTHER_DRUG (e_af ._af g_af ._af ,_af aminoglycosides_af ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
270,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,aminoglycosides,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
271,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,tetracyclines,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be OTHER_DRUG ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
272,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,bacitracin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be OTHER_DRUG ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
273,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,polymyxins,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
274,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,lincomycin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
275,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,clindamycin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
276,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,colistin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
277,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,sodium colistimethate,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
278,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,magnesium,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
279,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,lithium,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
280,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,anesthetics,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
281,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,procainamide,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
282,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,quinidine,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
283,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,contraceptives,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be OTHER_DRUG ,_af glucocorticoids_af ,_af certain_af monoamine_af oxidase_af inhibitors)_af drugs_af irreversibly_af inhibit_af plasma_af cholinesterase_af ._af Resistance_af neuromuscular_af blocking_af action_af nondepolarizing_af neuromuscular_af blocking_af agents_af demonstrated_af patients_af chronically_af administered_af phenytoin_af carbamazepine_af ._af"
284,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,glucocorticoids,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be OTHER_DRUG ,_af certain_af monoamine_af oxidase_af inhibitors)_af drugs_af irreversibly_af inhibit_af plasma_af cholinesterase_af ._af Resistance_af neuromuscular_af blocking_af action_af nondepolarizing_af neuromuscular_af blocking_af agents_af demonstrated_af patients_af chronically_af administered_af phenytoin_af carbamazepine_af ._af"
285,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,monoamine oxidase inhibitors,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be carbamazepine_be ._be"
286,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,phenytoin,effect,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf OTHER_DRUG carbamazepine_be ._be"
287,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,carbamazepine,effect,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf phenytoin_bf OTHER_DRUG ._be"
288,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,MIVACRON,effect,"While_bf effects_bf chronic_bf DRUG carbamazepine_be therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
289,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",carbamazepine,MIVACRON,effect,"While_bf effects_bf chronic_bf phenytoin_bf DRUG therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
290,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
291,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",spironolactone,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
292,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",triamterene,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be amiloride)_be potassium_be supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
293,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",amiloride,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
294,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf DRUG supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
295,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,ACE inhibitors,lithium,effect,Lithium:_bf Increased_bf serum_bf OTHER_DRUG levels_be symptoms_be OTHER_DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af OTHER_DRUG ._af
296,"If a diuretic is also used, the risk of lithium toxicity may be increased. ",diuretic,lithium,effect,"If_bf DRUG also_be used_be ,_be risk_be OTHER_DRUG toxicity_af may_af increased_af ._af"
297,"However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.",ketoconazole,mometasone furoate,mechanism,"However_bf ,_bf DRUG ,_be potent_be inhibitor_be cytochrome_be P450_be 3A4_be ,_be may_be increase_be plasma_be levels_be mometasone_be furoate_be concomitant_be dosing_be ._be"
298,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",phenobarbital,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf DRUG rifampin_be ,_be co-administered_be OTHER_DRUG ._af"
299,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",rifampin,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf phenobarbital_bf DRUG ,_be co-administered_be OTHER_DRUG ._af"
300,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",phenobarbital,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf DRUG rifampin_be ,_be co-administered_be OTHER_DRUG ._af"
301,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",rifampin,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf phenobarbital_bf DRUG ,_be co-administered_be OTHER_DRUG ._af"
302,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,CNS depressants,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
303,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,alcohol,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be OTHER_DRUG ,_af sedatives_af ,_af antihistaminics_af ,_af psychotropic_af drugs_af ._af"
304,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,sedatives,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be OTHER_DRUG ,_af antihistaminics_af ,_af psychotropic_af drugs_af ._af"
305,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,antihistaminics,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be OTHER_DRUG ,_af psychotropic_af drugs_af ._af"
306,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,psychotropic drugs,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
307,"Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",neuroleptics,morphine,effect,"Use_bf DRUG conjunction_be oral_be OTHER_DRUG may_af increase_af risk_af respiratory_af depression_af ,_af hypotension_af profound_af sedation_af coma_af ._af"
308,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
309,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",pentazocine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf DRUG ,_be nalbuphine_be ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
310,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",nalbuphine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf DRUG ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
311,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",butorphanol,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf DRUG ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
312,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",buprenorphine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
313,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,magnesium,mechanism,"Antacids:_bf Absorption_bf single_bf dose_bf DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be DRUG administered_af alone_af fasting_af conditions_af ._af"
314,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,aluminum,mechanism,"Antacids:_bf Absorption_bf single_bf dose_bf DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be DRUG administered_af alone_af fasting_af conditions_af ._af"
315,It is recommended that Myfortic and antacids not be administered simultaneously. ,Myfortic,antacids,advise,It_bf recommended_bf DRUG OTHER_DRUG administered_af simultaneously_af ._af
316,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,azathioprine,advise,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf OTHER_DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be DRUG administered_af concomitantly_af OTHER_DRUG mycophenolate_af mofetil_af ._af"
317,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,mycophenolate mofetil,advise,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf azathioprine_bf mycophenolate_bf mofetil_bf inhibit_bf purine_bf metabolism_bf ,_bf recommended_bf DRUG administered_be concomitantly_be azathioprine_be mycophenolate_be mofetil_be ._be"
318,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,cholestyramine,advise,"Therefore_bf ,_bf administer_bf DRUG OTHER_DRUG agents_af may_af interfere_af enterohepatic_af recirculation_af drugs_af may_af bind_af bile_af acids_af ,_af example_af bile_af acid_af sequestrates_af oral_af activated_af charcoal_af ,_af potential_af reduce_af efficacy_af DRUG ._af"
319,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,activated charcoal,advise,"Therefore_bf ,_bf administer_bf DRUG cholestyramine_be agents_be may_be interfere_be enterohepatic_be recirculation_be drugs_be may_be bind_be bile_be acids_be ,_be example_be bile_be acid_be sequestrates_be oral_be activated_be charcoal_be ,_be potential_be reduce_be efficacy_be DRUG ._af"
320,"However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. ",levonorgesterol,mycophenolate mofetil,mechanism,"However_bf ,_bf drug-drug_bf interaction_bf study_bf ,_bf mean_bf DRUG AUC_be decreased_be 15%_be coadministered_be mycophenolate_be mofetil_be ._be"
321,"Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. ",contraceptives,Myfortic,advise,"Therefore_bf ,_bf recommended_bf oral_bf DRUG co-_be administered_be OTHER_DRUG caution_af additional_af birth_af control_af methods_af considered_af ._af"
322,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",Myfortic,live attenuated vaccines,advise,"Live_bf Vaccines:_bf During_bf treatment_bf DRUG ,_be use_be live_be attenuated_be vaccines_be avoided_be patients_be advised_be vaccinations_be may_be less_be effective_be ._be"
323,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
324,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
325,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
326,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
327,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf OTHER_DRUG significantly_be increased_be OTHER_DRUG blood_af concentrations_af decreased_af ._af"
328,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf OTHER_DRUG significantly_be increased_be OTHER_DRUG blood_af concentrations_af decreased_af ._af"
329,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,effect,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG OTHER_DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af OTHER_DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
330,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,Alupent,advise,Other_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf OTHER_DRUG (metaproterenol_be sulfate_be USP)_be may_be additive_be effects_be ._be
331,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,metaproterenol sulfate,advise,Other_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf Alupent_bf (metaproterenol_bf sulfate_bf USP)_bf may_bf additive_bf effects_bf ._bf
332,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,monoamine oxidase inhibitors,advise,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
333,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,tricyclic antidepressants,advise,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
334,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,cyclosporine,mechanism,Cyclosporine:_bf Preliminary_bf data_bf DRUG OTHER_DRUG drug_af interaction_af study_af indicate_af reduction_af OTHER_DRUG plasma_af levels_af DRUG coadministered_af OTHER_DRUG ._af
335,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,beta-carotene,XENICAL,mechanism,Fat-soluble_bf Vitamin_bf Supplements_bf Analogues:_bf A_bf pharmacokinetic_bf interaction_bf study_bf showed_bf 30%_bf reduction_bf DRUG supplement_be absorption_be concomitantly_be administered_be OTHER_DRUG ._af
336,XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. ,XENICAL,vitamin E acetate,mechanism,DRUG inhibited_be absorption_be vitamin_be E_be acetate_be supplement_be approximately_be 60%_be ._be
337,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,mechanism,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf OTHER_DRUG ,_be patients_be chronic_be stable_be doses_be warfarin_be prescribed_be OTHER_DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
338,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",warfarin,XENICAL,advise,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf OTHER_DRUG ,_be patients_be chronic_be stable_be doses_be DRUG prescribed_af OTHER_DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
339,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,"DRUG ,_be bacteriostatic_be antibiotic_be ,_be may_be antagonize_be bactericidal_be effect_be OTHER_DRUG concurrent_af use_af drugs_af avoided_af ._af"
340,Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ,5-FU,ELOXATIN,mechanism,Increases_bf DRUG plasma_be concentrations_be approximately_be 20%_be observed_be doses_be 130_be mg/m2_be OTHER_DRUG dosed_af every_af 3_af weeks_af ._af
341,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,Anabolic steroids,anticoagulants,effect,OTHER_DRUG Anabolic_be steroids_be may_be increase_be sensitivity_be oral_be OTHER_DRUG ._af
342,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",oxandrolone,warfarin,mechanism,"Warfarin:_bf A_bf multidose_bf study_bf DRUG ,_be given_be 5_be 10_be mg_be BID_be 15_be healthy_be subjects_be concurrently_be treated_be OTHER_DRUG ,_af resulted_af mean_af increase_af S-warfarin_af half-life_af 26_af 48_af hours_af AUC_af 4_af ._af 55_af 12_af ._af 08_af ng*hr/mL:_af similar_af increases_af R-warfarin_af half-life_af AUC_af also_af detected_af ._af"
343,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,advise,"When_bf DRUG therapy_be initiated_be patient_be already_be receiving_be treatment_be OTHER_DRUG ,_af INR_af prothrombin_af time_af (PT)_af monitored_af closely_af dose_af OTHER_DRUG adjusted_af necessary_af stable_af target_af INR_af PT_af achieved_af ._af"
344,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. ",warfarin,oxandrolone,advise,"Furthermore_bf ,_bf patients_bf receiving_bf drugs_bf ,_bf careful_bf monitoring_bf INR_bf PT_bf ,_bf adjustment_bf DRUG dosage_be indicated_be recommended_be OTHER_DRUG dose_af changed_af discontinued_af ._af"
345,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,Oxandrolone,hypoglycemic agents,mechanism,Oral_bf hypoglycemic_bf agents_bf DRUG may_be inhibit_be metabolism_be oral_be hypoglycemic_be agents_be ._be
346,"The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ",oxybutynin,anticholinergic drugs,effect,"The_bf concomitant_bf use_bf DRUG anticholinergic_be drugs_be agents_be produce_be dry_be mouth_be ,_be constipation_be ,_be somnolence_be (drowsiness)_be ,_be and/or_be anticholinergic-like_be effects_be may_be increase_be frequency_be and/or_be severity_be effects_be ._be"
347,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",DITROPAN XL,ketoconazole,mechanism,"Mean_bf oxybutynin_bf chloride_bf plasma_bf concentrations_bf approximately_bf 2_bf fold_bf higher_bf DITROPAN_bf XL_bf administered_bf OTHER_DRUG ,_be potent_be CYP3A4_be inhibitor_be ._be"
348,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
349,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf DRUG miconazole)_be macrolide_be antibiotics_be (e_be ._be g_be ._be ,_be erythromycin_be clarithromycin)_be ,_be may_be alter_be OTHER_DRUG mean_af pharmacokinetic_af parameters_af (i_af ._af ._af ,_af Cmax_af AUC)_af ._af"
350,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
351,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
352,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",erythromycin,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG clarithromycin)_be ,_be may_be alter_be OTHER_DRUG mean_af pharmacokinetic_af parameters_af (i_af ._af ._af ,_af Cmax_af AUC)_af ._af"
353,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",clarithromycin,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
354,The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..,oxycodone hydrochloride,CNS depressants,effect,The_bf CNS_bf depressant_bf effects_bf oxycodone_bf hydrochloride_bf may_bf additive_bf CNS_bf depressants_bf ._bf ._bf
355,"Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ",Anticholinergics,opioid analgesics,effect,"DRUG medications_be anticholinergic_be activity_be used_be concurrently_be opioid_be analgesics_be may_be result_be increased_be risk_be urinary_be retention_be and/or_be severe_be constipation_be ,_be may_be lead_be paralytic_be ileus_be ._be"
356,It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. ,oxymorphone,propofol,effect,It_bf reported_bf incidence_bf bradycardia_bf increased_bf DRUG combined_be OTHER_DRUG induction_af anesthesia_af ._af
357,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; ",cimetidine,opioid analgesics,effect,"In_bf addition_bf ,_bf CNS_bf toxicity_bf reported_bf (confusion_bf ,_bf disorientation_bf ,_bf respiratory_bf depression_bf ,_bf apnea_bf ,_bf seizures)_bf following_bf coadministration_bf DRUG opioid_be analgesics;_be"
358,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,centrally acting drugs,advise,"Given_bf primary_bf CNS_bf effects_bf DRUG ,_be INVEGA_be used_be caution_be combination_be centrally_be acting_be drugs_be alcohol_be ._be"
359,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,alcohol,advise,"Given_bf primary_bf CNS_bf effects_bf DRUG ,_be INVEGA_be used_be caution_be combination_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
360,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,centrally acting drugs,advise,"Given_bf primary_bf CNS_bf effects_bf paliperidone_bf ,_bf DRUG used_be caution_be combination_be centrally_be acting_be drugs_be alcohol_be ._be"
361,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,alcohol,advise,"Given_bf primary_bf CNS_bf effects_bf paliperidone_bf ,_bf DRUG used_be caution_be combination_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
362,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,levodopa,effect,DRUG may_be antagonize_be effect_be OTHER_DRUG dopamine_af agonists_af ._af
363,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,dopamine agonists,effect,DRUG may_be antagonize_be effect_be levodopa_be dopamine_be agonists_be ._be
364,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",proton pump inhibitors,warfarin,effect,"There_bf postmarketing_bf reports_bf increased_bf INR_bf prothrombin_bf time_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf pantoprazole_bf ,_bf OTHER_DRUG concomitantly_be ._be"
365,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",pantoprazole,warfarin,effect,"There_bf postmarketing_bf reports_bf increased_bf INR_bf prothrombin_bf time_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf DRUG ,_be OTHER_DRUG concomitantly_af ._af"
366,Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. ,proton pump inhibitors,warfarin,advise,Patients_bf treated_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG concomitantly_be monitored_be increases_be INR_be prothrombin_be time_be ._be
367,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ketoconazole,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be OTHER_DRUG ,_af ampicillin_af esters_af ,_af iron_af salts)_af ._af"
368,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ampicillin,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be ketoconazole_be ,_be OTHER_DRUG esters_af ,_af iron_af salts)_af ._af"
369,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,iron,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be ketoconazole_be ,_be ampicillin_be esters_be ,_be OTHER_DRUG salts)_af ._af"
370,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,paricalcitol,mechanism,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be OTHER_DRUG AUC0-_af ._af Since_af OTHER_DRUG partially_af metabolized_af CYP3A_af DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af OTHER_DRUG DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
371,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf OTHER_DRUG approximately_be doubled_be DRUG AUC0-_af ._af Since_af DRUG partially_af metabolized_af CYP3A_af OTHER_DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG OTHER_DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
372,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,atazanavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af OTHER_DRUG ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
373,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,clarithromycin,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
374,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,indinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
375,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,itraconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
376,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nefazodone,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
377,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nelfinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
378,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ritonavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
379,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,saquinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
380,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,telithromycin,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af OTHER_DRUG voriconazole_af ._af"
381,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,voriconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af OTHER_DRUG ._af"
382,"Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. ",Zemplar,ketoconazole,advise,"Dose_bf adjustment_bf DRUG Capsules_be may_be required_be ,_be iPTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be OTHER_DRUG ._af"
383,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",fat-soluble vitamins,cholestyramine,mechanism,"Drugs_bf impair_bf intestinal_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf OTHER_DRUG ,_be may_be interfere_be absorption_be Zemplar_be Capsules_be ._be"
384,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",cholestyramine,Zemplar,mechanism,"Drugs_bf impair_bf intestinal_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf DRUG ,_be may_be interfere_be absorption_be OTHER_DRUG Capsules_af ._af"
385,patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.,lithium,Neulasta,advise,patients_bf receiving_bf DRUG OTHER_DRUG frequent_af monitoring_af neutrophil_af counts_af ._af
386,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,insulin,SOMAVERT,advise,Acromegalic_bf patients_bf diabetes_bf mellitus_bf treated_bf DRUG and/or_be oral_be hypoglycemic_be agents_be may_be require_be dose_be reductions_be therapeutic_be agents_be initiation_be therapy_be OTHER_DRUG ._af
387,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,hypoglycemic,SOMAVERT,advise,Acromegalic_bf patients_bf diabetes_bf mellitus_bf treated_bf insulin_bf and/or_bf oral_bf DRUG agents_be may_be require_be dose_be reductions_be therapeutic_be agents_be initiation_be therapy_be OTHER_DRUG ._af
388,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",opioids,pegvisomant,mechanism,"In_bf clinical_bf studies_bf ,_bf patients_bf DRUG often_be needed_be higher_be serum_be OTHER_DRUG concentrations_af achieve_af appropriate_af IGF-I_af suppression_af compared_af patients_af receiving_af DRUG ._af"
389,Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.,CYLERT,antiepileptic medications,effect,Decreased_bf seizure_bf threshold_bf reported_bf patients_bf receiving_bf DRUG concomitantly_be antiepileptic_be medications_be ._be
390,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",alcohol,pentazocine,advise,"Usage_bf Alcohol:_bf Due_bf potential_bf increased_bf CNS_bf depressants_bf effects_bf ,_bf DRUG used_be caution_be patients_be currently_be receiving_be OTHER_DRUG ._af"
391,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",TRENTAL,anticoagulants,effect,"Although_bf causal_bf relationship_bf established_bf ,_bf reports_bf bleeding_bf and/or_bf prolonged_bf prothrombin_bf time_bf patients_bf treated_bf DRUG without_be OTHER_DRUG platelet_af aggregation_af inhibitors_af ._af"
392,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",TRENTAL,platelet aggregation inhibitors,effect,"Although_bf causal_bf relationship_bf established_bf ,_bf reports_bf bleeding_bf and/or_bf prolonged_bf prothrombin_bf time_bf patients_bf treated_bf DRUG without_be anticoagulants_be platelet_be aggregation_be inhibitors_be ._be"
393,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,TRENTAL,theophylline,mechanism,Concomitant_bf administration_bf DRUG theophylline-containing_be drugs_be leads_be increased_be OTHER_DRUG levels_af OTHER_DRUG toxicity_af individuals_af ._af
394,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf OTHER_DRUG (a_be dopamine_be agonist);_be"
395,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,Permax,advise,"Dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
396,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf OTHER_DRUG (a_be dopamine_be agonist);_be"
397,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",butyrophenones,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
398,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",thioxanthines,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf DRUG )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
399,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",metoclopramide,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf DRUG ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
400,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",diuretics,ACEON,effect,"Diuretics:_bf Patients_bf DRUG ,_be especially_be started_be recently_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be OTHER_DRUG Tablets_af therapy_af ._af"
401,The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. ,diuretic,perindopril,effect,The_bf possibility_bf hypotensive_bf effects_bf minimized_bf either_bf discontinuing_bf DRUG increasing_be salt_be intake_be prior_be initiation_be treatment_be OTHER_DRUG ._af
402,"If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",diuretics,ACEON,advise,"If_bf DRUG cannot_be interrupted_be ,_be close_be medical_be supervision_be provided_be first_be dose_be OTHER_DRUG Tablets_af ,_af least_af two_af hours_af blood_af pressure_af stabilized_af another_af hour_af ._af"
403,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindopril,mechanism,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
404,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindoprilat,mechanism,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
405,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,perindopril,gentamicin,int,Gentamicin:_bf Animal_bf data_bf suggested_bf possibility_bf interaction_bf DRUG OTHER_DRUG ._af
406,Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.,alcohol,phentermine hydrochloride,int,Concomitant_bf use_bf DRUG phentermine_be hydrochloride_be may_be result_be adverse_be drug_be interaction_be ._be
407,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,halothane,effect,"DRUG ,_be particularly_be metaraminol_be ,_be may_be cause_be serious_be cardiac_be arrhythmias_be OTHER_DRUG anesthesia_af therefore_af used_af great_af caution_af ._af"
408,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,effect,"Vasopressors_bf ,_bf particularly_bf DRUG ,_be may_be cause_be serious_be cardiac_be arrhythmias_be OTHER_DRUG anesthesia_af therefore_af used_af great_af caution_af ._af"
409,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,monoamine oxidase inhibitors,effect,MAO_bf Inhibitors:_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
410,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,MAOI,effect,MAO_bf Inhibitors:_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
411,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,adrenergic agents,tricyclic antidepressants,effect,The_bf pressor_bf response_bf adrenergic_bf agents_bf may_bf also_bf potentiated_bf tricyclic_bf antidepressants_bf ._bf
412,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,halothane,effect,"DRUG ,_be particularly_be metaraminol_be ,_be may_be cause_be serious_be cardiac_be arrhythmias_be OTHER_DRUG anesthesia_af therefore_af used_af great_af caution_af ._af"
413,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,effect,"Vasopressors_bf ,_bf particularly_bf DRUG ,_be may_be cause_be serious_be cardiac_be arrhythmias_be OTHER_DRUG anesthesia_af therefore_af used_af great_af caution_af ._af"
414,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,monoamine oxidase inhibitors,effect,MAO_bf Inhibitors_bf -_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
415,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,MAOI,effect,MAO_bf Inhibitors_bf -_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
416,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,adrenergic agents,tricyclic antidepressants,effect,The_bf pressor_bf response_bf adrenergic_bf agents_bf may_bf also_bf potentiated_bf tricyclic_bf antidepressants_bf ._bf
417,Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. ,Pilocarpine,beta adrenergic antagonists,advise,DRUG administered_be caution_be patients_be taking_be beta_be adrenergic_be antagonists_be possibility_be conduction_be disturbances_be ._be
418,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. ",reserpine,beta-blocking agents,effect,"Catecholamine-depleting_bf drugs_bf (e_bf ._bf g_bf ._bf ,_bf reserpine)_bf may_bf additive_bf effect_bf given_bf beta-blocking_bf agents_bf ._bf"
419,Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. ,Pindolol,thioridazine,mechanism,DRUG shown_be increase_be serum_be OTHER_DRUG levels_af drugs_af co-administered_af ._af
420,Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER,advise,Other_bf short-acting_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf MAXAIR_bf AUTOHALER_bf may_bf additive_bf effects_bf ._bf
421,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,FELDENE,int,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf OTHER_DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be OTHER_DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
422,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",FELDENE,coumarin-type anticoagulants,advise,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
423,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,aspirin,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be OTHER_DRUG (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af piroxicam_af plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
424,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",Nonsteroidal anti-inflammatory agents,lithium,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf FELDENE_bf administered_bf conjunction_bf aspirin_bf (3900_bf mg/day)_bf ,_bf concomitant_bf administration_bf antacids_bf effect_bf piroxicam_bf plasma_bf levels_bf ._bf Nonsteroidal_bf anti-inflammatory_bf agents_bf ,_bf including_bf FELDENE_bf ,_bf reported_bf increase_bf steady_bf state_bf plasma_bf OTHER_DRUG levels_be ._be"
425,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,lithium,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be DRUG ,_af reported_af increase_af steady_af state_af plasma_af OTHER_DRUG levels_af ._af"
426,"It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.",lithium,FELDENE,advise,"It_bf recommended_bf plasma_bf DRUG levels_be monitored_be initiating_be ,_be adjusting_be discontinuing_be OTHER_DRUG ._af"
427,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",atropine,pralidoxime,effect,"When_bf DRUG OTHER_DRUG used_af together_af ,_af signs_af atropinization_af (flushing_af ,_af mydriasis_af ,_af tachycardia_af ,_af dryness_af mouth_af nose)_af may_af occur_af earlier_af might_af expected_af DRUG used_af alone_af ._af"
428,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",barbiturates,anticholinesterases,effect,"2_bf -_bf 4_bf The_bf following_bf precautions_bf kept_bf mind_bf treatment_bf anticholinesterase_bf poisoning_bf ,_bf although_bf bear_bf directly_bf use_bf pralidoxime:_bf since_bf DRUG potentiated_be OTHER_DRUG ,_af used_af cautiously_af treatment_af convulsions;_af"
429,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",Cimetidine,pramipexole,mechanism,"Cimetidine:_bf DRUG ,_be known_be inhibitor_be renal_be tubular_be secretion_be organic_be bases_be via_be cationic_be transport_be system_be ,_be caused_be 50%_be increase_be OTHER_DRUG AUC_af 40%_af increase_af half-life_af (N=_af 12)_af ._af"
430,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
431,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
432,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
433,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
434,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
435,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
436,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be OTHER_DRUG ._af"
437,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
438,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",penicillins,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
439,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",indomethacin,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
440,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",hydrochlorothiazide,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
441,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",chlorpropamide,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be OTHER_DRUG ._af"
442,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
443,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",neuroleptics,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
444,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",phenothiazines,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
445,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",butyrophenones,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
446,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",thioxanthenes,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
447,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",metoclopramide,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf DRUG ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
448,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
449,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
450,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
451,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
452,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
453,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
454,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,troleandomycin,corticosteroids,mechanism,Drugs_bf DRUG ketoconazole_be may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
455,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,ketoconazole,corticosteroids,mechanism,Drugs_bf troleandomycin_bf DRUG may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
456,Corticosteroids may increase the clearance of chronic high dose aspirin. ,Corticosteroids,aspirin,mechanism,DRUG may_be increase_be clearance_be chronic_be high_be dose_be OTHER_DRUG ._af
457,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,salicylate,corticosteroid,effect,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af OTHER_DRUG withdrawn_af ._af
458,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG patients_af suffering_af hypoprothrombinemia_af ._af
459,The effect of corticosteroids on oral anticoagulants is variable. ,corticosteroids,anticoagulants,effect,The_bf effect_bf DRUG oral_be OTHER_DRUG variable_af ._af
460,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. ,anticoagulants,corticosteroids,effect,There_bf reports_bf enhanced_bf well_bf diminished_bf effects_bf DRUG given_be concurrently_be OTHER_DRUG ._af
461,Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. ,Thiazide diuretics,phenothiazines,effect,Thiazide_bf diuretics_bf may_bf accentuate_bf orthostatic_bf hypotension_bf may_bf occur_bf OTHER_DRUG ._be
462,Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. ,guanethidine,phenothiazines,effect,Antihypertensive_bf effects_bf DRUG related_be compounds_be may_be counteracted_be OTHER_DRUG used_af concomitantly_af ._af
463,Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.,propranolol,phenothiazines,mechanism,Concomitant_bf administration_bf DRUG OTHER_DRUG results_af increased_af plasma_af levels_af drugs_af ._af
464,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,narcotics,effect,"The_bf induction_bf dose_bf requirements_bf DRUG Injectable_be Emulsion_be may_be reduced_be patients_be intramuscular_be intravenous_be premedication_be ,_be particularly_be OTHER_DRUG (eg_af ,_af morphine_af ,_af meperidine_af ,_af fentanyl_af ,_af etc_af ._af )_af"
465,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,morphine,effect,"The_bf induction_bf dose_bf requirements_bf DRUG Injectable_be Emulsion_be may_be reduced_be patients_be intramuscular_be intravenous_be premedication_be ,_be particularly_be narcotics_be (eg_be ,_be OTHER_DRUG ,_af meperidine_af ,_af fentanyl_af ,_af etc_af ._af )_af"
466,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,meperidine,effect,"The_bf induction_bf dose_bf requirements_bf DRUG Injectable_be Emulsion_be may_be reduced_be patients_be intramuscular_be intravenous_be premedication_be ,_be particularly_be narcotics_be (eg_be ,_be morphine_be ,_be OTHER_DRUG ,_af fentanyl_af ,_af etc_af ._af )_af"
467,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,fentanyl,effect,"The_bf induction_bf dose_bf requirements_bf DRUG Injectable_be Emulsion_be may_be reduced_be patients_be intramuscular_be intravenous_be premedication_be ,_be particularly_be narcotics_be (eg_be ,_be morphine_be ,_be meperidine_be ,_be OTHER_DRUG ,_af etc_af ._af )_af"
468,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,analgesic agents,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
469,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,nitrous oxide,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
470,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,opioids,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
471,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",propoxyphene,CNS depressants,effect,"The_bf CNS-depressant_bf effect_bf DRUG additive_be CNS_be depressants_be ,_be including_be alcohol_be ._be"
472,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",propoxyphene,alcohol,effect,"The_bf CNS-depressant_bf effect_bf DRUG additive_be CNS_be depressants_be ,_be including_be OTHER_DRUG ._af"
473,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,MAO inhibitors,pseudoephedrine,effect,MAO_bf inhibitors_bf beta_bf adrenergic_bf blockers_bf increase_bf effects_bf OTHER_DRUG ._be
474,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,beta adrenergic blockers,pseudoephedrine,effect,MAO_bf inhibitors_bf beta_bf adrenergic_bf blockers_bf increase_bf effects_bf OTHER_DRUG ._be
475,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,methyldopa,effect,"DRUG may_be reduce_be antihypertensive_be effects_be OTHER_DRUG ,_af mecamylamine_af ,_af reserpine_af veratrum_af alkaloids_af ._af"
476,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,mecamylamine,effect,"DRUG may_be reduce_be antihypertensive_be effects_be methyldopa_be ,_be OTHER_DRUG ,_af reserpine_af veratrum_af alkaloids_af ._af"
477,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,reserpine,effect,"DRUG may_be reduce_be antihypertensive_be effects_be methyldopa_be ,_be mecamylamine_be ,_be OTHER_DRUG veratrum_af alkaloids_af ._af"
478,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,veratrum alkaloids,effect,"DRUG may_be reduce_be antihypertensive_be effects_be methyldopa_be ,_be mecamylamine_be ,_be reserpine_be veratrum_be alkaloids_be ._be"
479,Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.,lorazepam,pyrimethamine,effect,Mild_bf hepatotoxicity_bf reported_bf patients_bf DRUG OTHER_DRUG administered_af concomitantly_af ._af
480,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,raloxifene,mechanism,Cholestyramine:_bf DRUG causes_be 60%_be reduction_be absorption_be enterohepatic_be cycling_be OTHER_DRUG coadministered_af EVISTA_af ._af
481,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,EVISTA,advise,Cholestyramine:_bf DRUG causes_be 60%_be reduction_be absorption_be enterohepatic_be cycling_be raloxifene_be coadministered_be OTHER_DRUG ._af
482,"If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. ",EVISTA,warfarin,advise,"If_bf DRUG given_be concurrently_be OTHER_DRUG ,_af prothrombin_af time_af monitored_af ._af"
483,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,clofibrate,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af naproxen_af ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
484,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,indomethacin,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be OTHER_DRUG ,_af naproxen_af ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
485,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,naproxen,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
486,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,ibuprofen,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be OTHER_DRUG ,_af diazepam_af ,_af diazoxide_af ._af"
487,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazepam,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be ibuprofen_be ,_be OTHER_DRUG ,_af diazoxide_af ._af"
488,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazoxide,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be ibuprofen_be ,_be diazepam_be ,_be OTHER_DRUG ._af"
489,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Alcohol,riboflavin,mechanism,Interactions_bf Vitamin_bf B2_bf (Riboflavin):_bf DRUG -_be impairs_be intestinal_be absorption_be OTHER_DRUG
490,Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; ,Probenecid,riboflavin,mechanism,DRUG -_be concurrent_be use_be decreases_be gastrointestinal_be absorption_be riboflavin;_be
491,requirements for riboflavin may be increased in patients receiving probenecid.,riboflavin,probenecid,effect,requirements_bf DRUG may_be increased_be patients_be receiving_be OTHER_DRUG ._af
492,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine HCl,Cimetidine,mechanism,"When_bf single_bf 100_bf mg_bf dose_bf rimantadine_bf HCl_bf administered_bf one_bf hour_bf initiation_bf OTHER_DRUG (300_be mg_be four_be times_be day)_be ,_be apparent_be total_be rimantadine_be clearance_be single_be dose_be normal_be healthy_be adults_be reduced_be 18%_be (compared_be apparent_be total_be rimantadine_be clearance_be subjects_be absence_be cimetidine)_be ._be"
493,Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%. ,acetaminophen,rimantadine,mechanism,Coadministration_bf DRUG reduced_be peak_be concentration_be AUC_be values_be OTHER_DRUG approximately_af 11%_af ._af
494,Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.,rimantadine,aspirin,mechanism,Peak_bf plasma_bf concentrations_bf AUC_bf DRUG reduced_be approximately_be 10%_be presence_be OTHER_DRUG ._af
495,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",cholinesterase inhibitors,anticholinergic medications,int,"Use_bf Anticholinergics:_bf Because_bf mechanism_bf action_bf ,_bf cholinesterase_bf inhibitors_bf potential_bf interfere_bf activity_bf anticholinergic_bf medications_bf ._bf"
496,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,succinylcholine,effect,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf OTHER_DRUG ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
497,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,neuromuscular blocking agents,effect,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf bethanechol_bf ._bf"
498,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,cholinergic agonists,effect,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf bethanechol_bf ._bf"
499,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,bethanechol,effect,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf OTHER_DRUG ._be"
500,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",ZEMURON,succinylcholine,advise,"If_bf DRUG administered_be following_be administration_be OTHER_DRUG ,_af given_af recovery_af OTHER_DRUG observed_af ._af"
501,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",Ropivacaine,anesthetics,advise,"DRUG used_be caution_be patients_be receiving_be local_be OTHER_DRUG agents_af structurally_af related_af amide-type_af local_af OTHER_DRUG ,_af since_af toxic_af effects_af drugs_af additive_af ._af"
502,"In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ",ropivacaine,fluvoxamine,mechanism,"In_bf vivo_bf ,_bf plasma_bf clearance_bf DRUG reduced_be 70%_be coadministration_be OTHER_DRUG (25_af mg_af bid_af 2_af days)_af ,_af selective_af potent_af CYP1A2_af inhibitor_af ._af"
503,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",fluvoxamine,Ropivacaine,int,"Thus_bf strong_bf inhibitors_bf cytochrome_bf P4501A2_bf ,_bf DRUG ,_be given_be concomitantly_be administration_be OTHER_DRUG ,_af interact_af OTHER_DRUG leading_af increased_af OTHER_DRUG plasma_af levels_af ._af"
504,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ketoconazole,ropivacaine,mechanism,"Coadministration_bf selective_bf potent_bf inhibitor_bf CYP3A4_bf ,_bf DRUG (100_be mg_be bid_be 2_be days_be OTHER_DRUG infusion_af administered_af 1_af hour_af ketoconazole)_af caused_af 15%_af reduction_af in-vivo_af plasma_af clearance_af OTHER_DRUG ._af"
505,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,gemfibrozil,rosiglitazone,mechanism,An_bf inhibitor_bf CYP2C8_bf (such_bf gemfibrozil)_bf may_bf increase_bf AUC_bf OTHER_DRUG inducer_be CYP2C8_be (such_be rifampin)_be may_be decrease_be AUC_be OTHER_DRUG ._af
506,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,rifampin,rosiglitazone,mechanism,An_bf inhibitor_bf CYP2C8_bf (such_bf gemfibrozil)_bf may_bf increase_bf AUC_bf OTHER_DRUG inducer_be CYP2C8_be (such_be rifampin)_be may_be decrease_be AUC_be OTHER_DRUG ._af
507,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,macrolides,terfenadine,int,Concomitant_bf administrations_bf recommended:_bf -_bf OTHER_DRUG astemizole:_be Certain_be DRUG interact_af OTHER_DRUG astemizole_af leading_af increased_af serum_af concentrations_af latter_af ._af
508,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,macrolides,astemizole,int,Concomitant_bf administrations_bf recommended:_bf -_bf Terfenadine_bf astemizole:_bf Certain_bf DRUG interact_be terfenadine_be OTHER_DRUG leading_af increased_af serum_af concentrations_af latter_af ._af
509,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,terfenadine,advise,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG OTHER_DRUG astemizole_af recommended_af ._af"
510,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,astemizole,advise,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG terfenadine_af OTHER_DRUG recommended_af ._af"
511,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",pimozide,macrolide antibacterials,mechanism,"-_bf Cisapride_bf ,_bf pimozide:_bf Other_bf drugs_bf cisapride_bf DRUG ,_be metabolised_be hepatic_be CYP3A_be isozymes_be associated_be QT_be interval_be prolongation_be and/or_be cardiac_be arrythmias_be (typically_be torsades_be de_be pointe)_be result_be increase_be serum_be level_be subsequent_be interaction_be significant_be inhibitors_be isozyme_be ,_be including_be macrolide_be antibacterials_be ._be"
512,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",cisapride,macrolide antibacterials,mechanism,"-_bf DRUG ,_be pimozide:_be Other_be drugs_be DRUG pimozide_af ,_af metabolised_af hepatic_af CYP3A_af isozymes_af associated_af QT_af interval_af prolongation_af and/or_af cardiac_af arrythmias_af (typically_af torsades_af de_af pointe)_af result_af increase_af serum_af level_af subsequent_af interaction_af significant_af inhibitors_af isozyme_af ,_af including_af macrolide_af antibacterials_af ._af"
513,"however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.",diphosphonate,Calcitonin (salmon),effect,"however_bf ,_bf patients_bf Paget's_bf Disease_bf prior_bf DRUG use_be appears_be reduce_be anti-resorptive_be response_be Calcitonin_be (salmon)_be nasal_be spray_be ._be"
514,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,ASPIRIN,DISALCID,effect,DRUG AND_be OTHER_be SALICYLATE_be DRUGS_be WILL_be BE_be ADDITIVE_be TO_be OTHER_DRUG AND_af MAY_af INCREASE_af PLASMA_af CONCENTRATIONS_af OF_af SALICYLIC_af ACID_af TO_af TOXIC_af LEVELS_af ._af
515,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,SALICYLATE DRUGS,DISALCID,effect,ASPIRIN_bf AND_bf OTHER_bf SALICYLATE_bf DRUGS_bf WILL_bf BE_bf ADDITIVE_bf TO_bf OTHER_DRUG AND_be MAY_be INCREASE_be PLASMA_be CONCENTRATIONS_be OF_be SALICYLIC_be ACID_be TO_be TOXIC_be LEVELS_be ._be
516,Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding. ,Salicylates,anticoagulant drugs,effect,DRUG given_be concomitantly_be anticoagulant_be drugs_be may_be predispose_be systemic_be bleeding_be ._be
517,Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. ,Salicylates,antidiabetic drugs,effect,DRUG may_be enhance_be hypoglycemic_be effect_be oral_be antidiabetic_be drugs_be sulfonylurea_be class_be ._be
518,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,penicillin,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be OTHER_DRUG ,_af thiopental_af ,_af thyroxine_af ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
519,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,thiopental,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be OTHER_DRUG ,_af thyroxine_af ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
520,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,thyroxine,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be OTHER_DRUG ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
521,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,triiodothyronine,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
522,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,phenytoin,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be OTHER_DRUG ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
523,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,sulfinpyrazone,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
524,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,naproxen,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be OTHER_DRUG ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
525,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,warfarin,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
526,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,methotrexate,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
527,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,corticosteroids,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
528,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",Leukine,lithium,effect,"Drugs_bf may_bf potentiate_bf myeloproliferative_bf effects_bf DRUG ,_be OTHER_DRUG corticosteroids_af ,_af used_af caution_af ._af"
529,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",Leukine,corticosteroids,effect,"Drugs_bf may_bf potentiate_bf myeloproliferative_bf effects_bf DRUG ,_be lithium_be OTHER_DRUG ,_af used_af caution_af ._af"
530,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",digoxin,sitagliptin,mechanism,"Digoxin:_bf There_bf slight_bf increase_bf area_bf curve_bf (AUC_bf ,_bf 11%)_bf mean_bf peak_bf drug_bf concentration_bf (Cmax_bf ,_bf 18%)_bf DRUG co-administration_be 100_be mg_be OTHER_DRUG 10_af days_af ._af"
531,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,norepinephrine,sodium bicarbonate,int,DRUG dobutamine_be incompatible_be sodium_be bicarbonate_be solution_be ._be
532,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,dobutamine,sodium bicarbonate,int,norepinephrine_bf DRUG incompatible_be sodium_be bicarbonate_be solution_be ._be
533,Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. ,VESIcare,ketoconazole,advise,Do_bf exceed_bf 5_bf mg_bf daily_bf dose_bf DRUG administered_be therapeutic_be doses_be OTHER_DRUG potent_af CYP3A4_af inhibitors_af ._af
534,Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. ,GH,antipyrine,mechanism,Limited_bf published_bf data_bf indicate_bf DRUG treatment_be increases_be cytochrome_be P450_be (CP450)_be mediated_be OTHER_DRUG clearance_af man_af ._af
535,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,corticosteroids,mechanism,"These_bf data_bf suggest_bf DRUG administration_be may_be alter_be clearance_be compounds_be known_be metabolized_be CP450_be liver_be enzymes_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af sex_af steroids_af ,_af anticonvulsants_af ,_af cyclosporin)_af ._af"
536,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,sex steroids,mechanism,"These_bf data_bf suggest_bf DRUG administration_be may_be alter_be clearance_be compounds_be known_be metabolized_be CP450_be liver_be enzymes_be (e_be ._be g_be ._be ,_be corticosteroids_be ,_be sex_be steroids_be ,_be anticonvulsants_be ,_be cyclosporin)_be ._be"
537,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,anticonvulsants,mechanism,"These_bf data_bf suggest_bf DRUG administration_be may_be alter_be clearance_be compounds_be known_be metabolized_be CP450_be liver_be enzymes_be (e_be ._be g_be ._be ,_be corticosteroids_be ,_be sex_be steroids_be ,_be OTHER_DRUG ,_af cyclosporin)_af ._af"
538,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,cyclosporin,mechanism,"These_bf data_bf suggest_bf DRUG administration_be may_be alter_be clearance_be compounds_be known_be metabolized_be CP450_be liver_be enzymes_be (e_be ._be g_be ._be ,_be corticosteroids_be ,_be sex_be steroids_be ,_be anticonvulsants_be ,_be cyclosporin)_be ._be"
539,Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). ,NEXAVAR,irinotecan,advise,Caution_bf recommended_bf administering_bf DRUG compounds_be metabolized/eliminated_be predominantly_be UGT1A1_be pathway_be (e_be ._be g_be ._be irinotecan)_be ._be
540,Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. ,NEXAVAR,doxorubicin,mechanism,Concomitant_bf treatment_bf DRUG resulted_be 21%_be increase_be AUC_be OTHER_DRUG ._af
541,Caution is recommended when administering doxorubicin with NEXAVAR. ,doxorubicin,NEXAVAR,advise,Caution_bf recommended_bf administering_bf DRUG OTHER_DRUG ._af
542,Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. ,Zidovudine,stavudine,effect,DRUG competitively_be inhibits_be intracellular_be phosphorylation_be OTHER_DRUG ._af
543,"Therefore, use of zidovudine in combination with ZERIT should be avoided. ",zidovudine,ZERIT,advise,"Therefore_bf ,_bf use_bf DRUG combination_be OTHER_DRUG avoided_af ._af"
544,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,stavudine,doxorubicin,effect,In_bf vitro_bf data_bf indicate_bf phosphorylation_bf DRUG also_be inhibited_be relevant_be concentrations_be OTHER_DRUG ribavirin_af ._af
545,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,stavudine,ribavirin,effect,In_bf vitro_bf data_bf indicate_bf phosphorylation_bf DRUG also_be inhibited_be relevant_be concentrations_be doxorubicin_be OTHER_DRUG ._af
546,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,antiplatelet agents,effect,"Use_bf Anticoagulants_bf Antiplatelet_bf Agents_bf --_bf DRUG ,_be Streptokinase_be ,_be alone_be combination_be antiplatelet_be agents_be anticoagulants_be ,_be may_be cause_be bleeding_be complications_be ._be"
547,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,anticoagulants,effect,"Use_bf OTHER_DRUG Antiplatelet_be Agents_be --_be DRUG ,_af Streptokinase_af ,_af alone_af combination_af antiplatelet_af agents_af OTHER_DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
548,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptokinase,antiplatelet agents,effect,"Use_bf Anticoagulants_bf Antiplatelet_bf Agents_bf --_bf Streptase_bf ,_bf DRUG ,_be alone_be combination_be antiplatelet_be agents_be anticoagulants_be ,_be may_be cause_be bleeding_be complications_be ._be"
549,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptokinase,anticoagulants,effect,"Use_bf OTHER_DRUG Antiplatelet_be Agents_be --_be Streptase_be ,_be DRUG ,_af alone_af combination_af antiplatelet_af agents_af OTHER_DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
550,"The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",aspirin,Streptokinase,effect,"The_bf addition_bf DRUG OTHER_DRUG causes_af minimal_af increase_af risk_af minor_af bleeding_af (3_af ._af 9%_af vs_af ._af 3_af ._af 1%)_af ,_af appear_af increase_af incidence_af major_af bleeding_af (see_af"
551,Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; ,Streptozocin,doxorubicin,mechanism,DRUG reported_be prolong_be elimination_be half-life_be OTHER_DRUG may_af lead_af severe_af bone_af marrow_af suppression;_af
552,a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. ,doxorubicin,ZANOSAR,advise,reduction_bf DRUG dosage_be considered_be patients_be receiving_be OTHER_DRUG concurrently_af ._af
553,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,streptozocin,phenytoin,effect,The_bf concurrent_bf use_bf DRUG OTHER_DRUG reported_af one_af case_af result_af reduced_af DRUG cytotoxicity_af ._af
554,"Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. ",CHEMET,CaNa 2 EDTA,advise,"Concomitant_bf administration_bf DRUG chelation_be therapy_be ,_be CaNa_be 2_be EDTA_be recommended_be ._be"
555,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,barbiturates,effect,"DRUG may_be increase_be effects_be OTHER_DRUG ,_af tolbutamide_af ,_af uricosurics_af ._af"
556,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,tolbutamide,effect,"DRUG may_be increase_be effects_be barbiturates_be ,_be OTHER_DRUG ,_af uricosurics_af ._af"
557,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,uricosurics,effect,"DRUG may_be increase_be effects_be barbiturates_be ,_be tolbutamide_be ,_be OTHER_DRUG ._af"
558,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,sulfamethoxazole,warfarin,effect,It_bf reported_bf DRUG may_be prolong_be prothrombin_be time_be patients_be receiving_be anticoagulant_be OTHER_DRUG ._af
559,Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. ,Sulfamethoxazole,phenytoin,mechanism,DRUG may_be inhibit_be hepatic_be metabolism_be OTHER_DRUG ._af
560,"At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. ",sulfamethoxazole,phenytoin,mechanism,"At_bf 1_bf ._bf 6-g_bf dose_bf ,_bf DRUG produced_be slight_be significant_be increase_be half-life_be OTHER_DRUG produce_af corresponding_af decrease_af metabolic_af clearance_af rate_af ._af"
561,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",Sulfonamides,methotrexate,mechanism,"DRUG also_be displace_be OTHER_DRUG plasma_af protein-binding_af sites_af ,_af thus_af increasing_af free_af OTHER_DRUG concentrations_af ._af"
562,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,barbiturates,effect,"DRUG may_be increase_be effects_be OTHER_DRUG ,_af tolbutamide_af ,_af uricosurics_af ._af"
563,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,tolbutamide,effect,"DRUG may_be increase_be effects_be barbiturates_be ,_be OTHER_DRUG ,_af uricosurics_af ._af"
564,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,uricosurics,effect,"DRUG may_be increase_be effects_be barbiturates_be ,_be tolbutamide_be ,_be OTHER_DRUG ._af"
565,"However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. ",FLOMAX,alpha-adrenergic blocking agents,advise,"However_bf ,_bf interactions_bf may_bf expected_bf DRUG capsules_be NOT_be used_be combination_be alpha-adrenergic_be blocking_be agents_be ._be"
566,"Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. ",FLOMAX,cimetidine,advise,"Therefore_bf ,_bf DRUG capsules_be used_be caution_be combination_be OTHER_DRUG ,_af particularly_af doses_af higher_af 0_af ._af 4_af mg_af ._af"
567,"Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        ",warfarin,FLOMAX,advise,"Therefore_bf ,_bf caution_bf exercised_bf concomitant_bf administration_bf DRUG OTHER_DRUG capsules_af ._af"
568,Administration of valproic acid decreases oral clearance of temozolomide by about 5%. ,valproic acid,temozolomide,mechanism,Administration_bf valproic_bf acid_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 5%_be ._be
569,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",Anticoagulants,TNKase,effect,"DRUG (such_be heparin_be vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be dipyridamole_be ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be OTHER_DRUG therapy_af ._af"
570,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",heparin,TNKase,effect,"Anticoagulants_bf (such_bf DRUG vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be dipyridamole_be ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be OTHER_DRUG therapy_af ._af"
571,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",vitamin K antagonists,TNKase,effect,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf dipyridamole_bf ,_bf GP_bf IIb/IIIa_bf inhibitors)_bf may_bf increase_bf risk_bf bleeding_bf administered_bf prior_bf ,_bf ,_bf OTHER_DRUG therapy_be ._be"
572,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",acetylsalicylic acid,TNKase,effect,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf dipyridamole_bf ,_bf GP_bf IIb/IIIa_bf inhibitors)_bf may_bf increase_bf risk_bf bleeding_bf administered_bf prior_bf ,_bf ,_bf OTHER_DRUG therapy_be ._be"
573,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",dipyridamole,TNKase,effect,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf DRUG ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be OTHER_DRUG therapy_af ._af"
574,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",tolbutamide,teniposide,mechanism,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf DRUG ,_be sodium_be salicylate_be sulfamethizole_be displaced_be protein-bound_be OTHER_DRUG fresh_af human_af serum_af small_af significant_af extent_af ._af"
575,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sodium salicylate,teniposide,mechanism,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf tolbutamide_bf ,_bf sodium_bf salicylate_bf sulfamethizole_bf displaced_bf protein-bound_bf OTHER_DRUG fresh_be human_be serum_be small_be significant_be extent_be ._be"
576,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sulfamethizole,teniposide,mechanism,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf tolbutamide_bf ,_bf sodium_bf salicylate_bf DRUG displaced_be protein-bound_be OTHER_DRUG fresh_af human_af serum_af small_af significant_af extent_af ._af"
577,An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.,methotrexate,teniposide,mechanism,An_bf increase_bf intracellular_bf levels_bf DRUG observed_be vitro_be presence_be OTHER_DRUG ._af
578,Terbinafine decreases the clearance of caffeine by 19%. ,Terbinafine,caffeine,mechanism,DRUG decreases_be clearance_be OTHER_DRUG 19%_af ._af
579,Terbinafine increases the clearance of cyclosporine by 15%. ,Terbinafine,cyclosporine,mechanism,DRUG increases_be clearance_be OTHER_DRUG 15%_af ._af
580,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",terbinafine,warfarin,effect,"There_bf spontaneous_bf reports_bf increase_bf decrease_bf prothrombin_bf times_bf patients_bf concomitantly_bf taking_bf oral_bf DRUG OTHER_DRUG ,_af however_af ,_af causal_af relationship_af LAMISIL_af Tablets_af changes_af established_af ._af"
581,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",Terbinafine,rifampin,mechanism,"DRUG clearance_be increased_be 100%_be OTHER_DRUG ,_af CyP450_af enzyme_af inducer_af ,_af decreased_af 33%_af cimetidine_af ,_af CyP450_af enzyme_af inhibitor_af ._af"
582,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",Terbinafine,cimetidine,mechanism,"DRUG clearance_be increased_be 100%_be rifampin_be ,_be CyP450_be enzyme_be inducer_be ,_be decreased_be 33%_be OTHER_DRUG ,_af CyP450_af enzyme_af inhibitor_af ._af"
583,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",ketoconazole,terfenadine,effect,"Ketoconazole:_bf Spontaneous_bf adverse_bf reaction_bf reports_bf patients_bf taking_bf concomitant_bf DRUG recommended_be doses_be OTHER_DRUG demonstrate_af QT_af interval_af prolongation_af rare_af serious_af cardiac_af events_af ,_af ._af g_af ._af"
584,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",ketoconazole,terfenadine,mechanism,"Pharmacokinetic_bf data_bf indicate_bf DRUG markedly_be inhibits_be metabolism_be OTHER_DRUG ,_af resulting_af elevated_af plasma_af OTHER_DRUG levels_af ._af"
585,Concomitant administration of ketoconazole and terfenadine is contraindicated. ,ketoconazole,terfenadine,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
586,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,terfenadine,itraconazole,mechanism,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf DRUG levels_be reported_be concomitant_be use_be DRUG OTHER_DRUG clinical_af trials_af OTHER_DRUG foreign_af post-marketing_af sources_af ._af
587,Concomitant administration of itraconazole and terfenadine is contraindicated. ,itraconazole,terfenadine,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
588,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf concomitant_bf use_bf products_bf OTHER_DRUG recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
589,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf DRUG ,_be metronidazole_be ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be OTHER_DRUG recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
590,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",metronidazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf DRUG ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be OTHER_DRUG recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
591,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",miconazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf concomitant_bf use_bf products_bf OTHER_DRUG recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
592,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",erythromycin,terfenadine,mechanism,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf DRUG clarithromycin_be exert_be effect_be OTHER_DRUG metabolism_af mechanism_af may_af similar_af ketoconazole_af ,_af lesser_af extent_af ._af"
593,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",clarithromycin,terfenadine,mechanism,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf erythromycin_bf DRUG exert_be effect_be OTHER_DRUG metabolism_af mechanism_af may_af similar_af ketoconazole_af ,_af lesser_af extent_af ._af"
594,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,clarithromycin,advise,"Concomitant_bf administration_bf DRUG OTHER_DRUG ,_af erythromycin_af ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
595,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,erythromycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be OTHER_DRUG ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
596,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,troleandomycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be OTHER_DRUG contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
597,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,macrolide antibiotics,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
598,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,azithromycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af OTHER_DRUG ,_af recommended_af ._af"
599,"When administered concurrently, testolactone may increase the effects of oral anticoagulants; ",testolactone,anticoagulants,effect,"When_bf administered_bf concurrently_bf ,_bf DRUG may_be increase_be effects_be oral_be anticoagulants;_be"
600,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",Thalidomide,barbiturates,effect,"DRUG reported_be enhance_be sedative_be activity_be OTHER_DRUG ,_af alcohol_af ,_af chlorpromazine_af ,_af reserpine_af ._af"
601,John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ,John's Wort,hormonal contraceptive agents,effect,John's_bf Wort_bf hormonal_bf contraceptive_bf agents_bf may_bf reduce_bf effectiveness_bf contraception_bf one_bf month_bf discontinuation_bf concomitant_bf therapies_bf ._bf
602,"Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",Thiabendazole,theophylline,mechanism,"DRUG may_be compete_be drugs_be ,_be OTHER_DRUG ,_af sites_af metabolism_af liver_af ,_af thus_af elevating_af serum_af levels_af compounds_af potentially_af toxic_af levels_af ._af"
603,"Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",thiabendazole,xanthine derivatives,advise,"Therefore_bf ,_bf concomitant_bf use_bf DRUG xanthine_be derivatives_be anticipated_be ,_be may_be necessary_be monitor_be blood_be levels_be and/or_be reduce_be dosage_be compounds_be ._be"
604,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Loop Diuretics,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
605,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Contraceptives,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf OTHER_DRUG ,_be Stavudine_be ,_be Tricyclic_be Antidepressants_be"
606,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Stavudine,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf OTHER_DRUG ,_be Tricyclic_be Antidepressants_be"
607,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Tricyclic Antidepressants,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
608,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Loop Diuretics,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
609,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Contraceptives,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf OTHER_DRUG ,_be Stavudine_be ,_be Tricyclic_be Antidepressants_be"
610,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Stavudine,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf OTHER_DRUG ,_be Tricyclic_be Antidepressants_be"
611,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Tricyclic Antidepressants,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
612,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,CNS depressants,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be anesthetics_be ,_be opiates_be ,_be alcohol_be ,_be etc_be ._be )_be"
613,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,barbiturates,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af anesthetics_af ,_af opiates_af ,_af alcohol_af ,_af etc_af ._af )_af"
614,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,anesthetics,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be OTHER_DRUG ,_af opiates_af ,_af alcohol_af ,_af etc_af ._af )_af"
615,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,opiates,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be anesthetics_be ,_be OTHER_DRUG ,_af alcohol_af ,_af etc_af ._af )_af"
616,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,alcohol,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be anesthetics_be ,_be opiates_be ,_be OTHER_DRUG ,_af etc_af ._af )_af"
617,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,TABLOID,effect,There_bf usually_bf complete_bf cross-resistance_bf DRUG (mercaptopurine)_be OTHER_DRUG brand_af Thioguanine_af ._af
618,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,Thioguanine,effect,There_bf usually_bf complete_bf cross-resistance_bf DRUG (mercaptopurine)_be TABLOID_be brand_be OTHER_DRUG ._af
619,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,mercaptopurine,TABLOID,effect,There_bf usually_bf complete_bf cross-resistance_bf PURINETHOL_bf (mercaptopurine)_bf OTHER_DRUG brand_be Thioguanine_be ._be
620,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,mercaptopurine,Thioguanine,effect,There_bf usually_bf complete_bf cross-resistance_bf PURINETHOL_bf (mercaptopurine)_bf TABLOID_bf brand_bf OTHER_DRUG ._be
621,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",aminosalicylate derivatives,thioguanine,mechanism,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf mesalazine_bf ,_bf sulphasalazine)_bf inhibit_bf TPMT_bf enzyme_bf ,_bf administered_bf caution_bf patients_bf receiving_bf concurrent_bf OTHER_DRUG therapy_be ._be"
622,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",olsalazine,thioguanine,mechanism,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be mesalazine_be ,_be sulphasalazine)_be inhibit_be TPMT_be enzyme_be ,_be administered_be caution_be patients_be receiving_be concurrent_be OTHER_DRUG therapy_af ._af"
623,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",mesalazine,thioguanine,mechanism,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf DRUG ,_be sulphasalazine)_be inhibit_be TPMT_be enzyme_be ,_be administered_be caution_be patients_be receiving_be concurrent_be OTHER_DRUG therapy_af ._af"
624,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",sulphasalazine,thioguanine,mechanism,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf mesalazine_bf ,_bf sulphasalazine)_bf inhibit_bf TPMT_bf enzyme_bf ,_bf administered_bf caution_bf patients_bf receiving_bf concurrent_bf OTHER_DRUG therapy_be ._be"
625,Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. ,ZADAXIN,immunomodulating drugs,advise,Caution_bf exercised_bf administering_bf DRUG therapy_be combination_be immunomodulating_be drugs_be ._be
626,Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.   ,tigecycline,warfarin,advise,Prothrombin_bf time_bf suitable_bf anticoagulation_bf test_bf monitored_bf DRUG administered_be OTHER_DRUG ._af
627,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,antibacterial drugs,contraceptives,effect,Concurrent_bf use_bf antibacterial_bf drugs_bf oral_bf OTHER_DRUG may_be render_be oral_be OTHER_DRUG less_af effective_af ._af
628,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,calcium,mechanism,"The_bf bioavailability_bf DRUG decreased_be 80%_be OTHER_DRUG ,_af OTHER_DRUG DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
629,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",aluminum,SKELID,mechanism,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be calcium_be ,_be calcium_be OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
630,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",magnesium,SKELID,mechanism,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be calcium_be ,_be calcium_be OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
631,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,Aspirin,SKELID,mechanism,DRUG may_be decrease_be bioavailability_be OTHER_DRUG 50%_af taken_af 2_af hours_af OTHER_DRUG ._af
632,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,SKELID,indomethacin,mechanism,The_bf bioavailability_bf DRUG increased_be 2-4_be fold_be OTHER_DRUG significantly_af altered_af coadministration_af diclofenac_af ._af
633,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,anticholinergic,advise,"However_bf ,_bf co_bf administration_bf DRUG OTHER_DRUG containing_af drugs_af (e_af ._af g_af ._af ,_af ipratropium)_af studied_af therefore_af recommended_af ._af"
634,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,ipratropium,advise,"However_bf ,_bf co_bf administration_bf DRUG anticholinergic_be containing_be drugs_be (e_be ._be g_be ._be ,_be ipratropium)_be studied_be therefore_be recommended_be ._be"
635,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,heparin,effect,"The_bf use_bf DRUG ,_be combination_be OTHER_DRUG aspirin_af ,_af associated_af increase_af bleeding_af compared_af OTHER_DRUG aspirin_af alone_af (see_af"
636,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,aspirin,effect,"The_bf use_bf DRUG ,_be combination_be heparin_be OTHER_DRUG ,_af associated_af increase_af bleeding_af compared_af heparin_af OTHER_DRUG alone_af (see_af"
637,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,dornase alfa,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
638,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,PULMOZYME,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
639,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,(beta)-agonists,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af OTHER_DRUG ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
640,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,corticosteroids,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af OTHER_DRUG ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
641,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,anti-pseudomonal antibiotics,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
642,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,aminoglycosides,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af OTHER_DRUG demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
643,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,diuretics,aminoglycoside,effect,Some_bf DRUG enhance_be OTHER_DRUG toxicity_af altering_af antibiotic_af concentrations_af serum_af tissue_af ._af
644,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,ethacrynic acid,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be urea_be ,_be mannitol_be ._be"
645,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,furosemide,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be OTHER_DRUG ,_af urea_af ,_af mannitol_af ._af"
646,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,urea,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be OTHER_DRUG ,_af mannitol_af ._af"
647,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,mannitol,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be urea_be ,_be OTHER_DRUG ._af"
648,"However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. ",TOLECTIN,warfarin,effect,"However_bf ,_bf increased_bf prothrombin_bf time_bf bleeding_bf reported_bf patients_bf concomitant_bf DRUG OTHER_DRUG therapy_af ._af"
649,"Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. ",TOLECTIN,anticoagulants,advise,"Therefore_bf ,_bf caution_bf exercised_bf administering_bf DRUG patients_be OTHER_DRUG ._af"
650,Caution should be used if TOLECTIN is administered concomitantly with methotrexate. ,TOLECTIN,methotrexate,advise,Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
651,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",TOLECTIN,methotrexate,mechanism,"DRUG nonsteroidal_be anti-inflammatory_be drugs_be reported_be reduce_be tubular_be secretion_be OTHER_DRUG animal_af model_af ,_af possibly_af enhancing_af toxicity_af OTHER_DRUG ._af"
652,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,"TOLECTIN_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf reported_bf reduce_bf tubular_bf secretion_bf OTHER_DRUG animal_be model_be ,_be possibly_be enhancing_be toxicity_be OTHER_DRUG ._af"
653,"CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ",Ketoconazole,tolterodine,mechanism,"CYP3A4_bf Inhibitors:_bf DRUG ,_be inhibitor_be drug_be metabolizing_be enzyme_be CYP3A4_be ,_be significantly_be increased_be plasma_be concentrations_be OTHER_DRUG coadministered_af subjects_af poor_af metabolizers_af (see_af CLINICAL_af PHARMACOLOGY_af ,_af Variability_af Metabolism_af Drug-Drug_af Interactions)_af ._af"
654,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
655,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
656,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
657,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
658,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
659,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",erythromycin,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf DRUG ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
660,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",clarithromycin,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
661,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",cyclosporine,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf DRUG vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
662,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",vinblastine,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf DRUG ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
663,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,paclitaxel,HERCEPTIN,mechanism,Administration_bf DRUG combination_be OTHER_DRUG resulted_af two-fold_af decrease_af OTHER_DRUG clearance_af non-human_af primate_af study_af 1_af ._af 5-fold_af increase_af OTHER_DRUG serum_af levels_af clinical_af studies_af ._af
664,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,Trilostane,aminoglutethimide,int,DRUG may_be interact_be OTHER_DRUG mitotane_af (causing_af great_af decrease_af adrenal_af function)_af ._af
665,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,Trilostane,mitotane,int,DRUG may_be interact_be aminoglutethimide_be OTHER_DRUG (causing_af great_af decrease_af adrenal_af function)_af ._af
666,Trimethoprim may inhibit the hepatic metabolism of phenytoin. ,Trimethoprim,phenytoin,mechanism,DRUG may_be inhibit_be hepatic_be metabolism_be OTHER_DRUG ._af
667,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,mechanism,"DRUG ,_be given_be common_be clinical_be dosage_be ,_be increased_be OTHER_DRUG half-life_af 51%_af decreased_af OTHER_DRUG metabolic_af clearance_af rate_af 30%_af ._af"
668,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,mechanism,"DRUG ,_be given_be common_be clinical_be dosage_be ,_be increased_be OTHER_DRUG half-life_af 51%_af decreased_af OTHER_DRUG metabolic_af clearance_af rate_af 30%_af ._af"
669,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,central nervous system depressants,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
670,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,alcohol,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be OTHER_DRUG ,_af barbiturates_af ,_af hypnotics_af ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
671,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,barbiturates,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be OTHER_DRUG ,_af hypnotics_af ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
672,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,hypnotics,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
673,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,narcotic analgesics,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
674,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,sedatives,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af tranquillisers_af ._af"
675,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,tranquillisers,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be OTHER_DRUG ._af"
676,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",anticholinergic drugs,triprolidine,effect,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf atropine_bf tricyclic_bf antidepressants_bf may_bf enhanced_bf concomitant_bf administration_bf OTHER_DRUG ._be"
677,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",atropine,triprolidine,effect,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf DRUG tricyclic_be antidepressants_be may_be enhanced_be concomitant_be administration_be OTHER_DRUG ._af"
678,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",tricyclic antidepressants,triprolidine,effect,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf atropine_bf tricyclic_bf antidepressants_bf may_bf enhanced_bf concomitant_bf administration_bf OTHER_DRUG ._be"
679,"The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ",Sanctura,anticholinergic agents,effect,"The_bf concomitant_bf use_bf DRUG anticholinergic_be agents_be produce_be dry_be mouth_be ,_be constipation_be ,_be anticholinergic_be pharmacological_be effects_be may_be increase_be frequency_be and/or_be severity_be effects_be ._be"
680,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,digoxin,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af OTHER_DRUG ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
681,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,procainamide,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af OTHER_DRUG ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
682,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,pancuronium,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af OTHER_DRUG ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
683,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,morphine,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af OTHER_DRUG ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
684,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,vancomycin,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af OTHER_DRUG ,_af metformin_af tenofovir)_af ._af"
685,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,metformin,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af OTHER_DRUG tenofovir)_af ._af"
686,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,tenofovir,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
687,Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,vancomycin,anesthetic agents,effect,Concomitant_bf administration_bf DRUG anesthetic_be agents_be associated_be erythema_be histamine-like_be flushing_be anaphylactoid_be reactions_be ._be
688,A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. ,vigabatrin,carbamazepine,mechanism,A_bf study_bf published_bf 2002_bf found_bf DRUG causes_be statistically_be significant_be increase_be plasma_be clearance_be OTHER_DRUG ._af
689,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,mechanism,"In_bf 1984_bf ,_bf Drs_bf Rimmer_bf Richens_bf University_bf Wales_bf reported_bf administering_bf DRUG OTHER_DRUG lowered_af serum_af OTHER_DRUG concentration_af patients_af treatment-resistant_af epilepsy_af ._af"
690,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Phenytoin,int,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be vaccine_be virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be vaccine_be -_be Mitomycin-C:_be may_be cause_be shortness_be breath_be bronchospasm_be -_be Killed_be virus_be vaccines:_be may_be decrease_be patient's_be response_be vaccine_be"
691,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Live virus vaccines,int,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be vaccine_be virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be vaccine_be -_be Mitomycin-C:_be may_be cause_be shortness_be breath_be bronchospasm_be -_be Killed_be virus_be vaccines:_be may_be decrease_be patient's_be response_be vaccine_be"
692,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Mitomycin-C,int,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be vaccine_be virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be vaccine_be -_be Mitomycin-C:_be may_be cause_be shortness_be breath_be bronchospasm_be -_be Killed_be virus_be vaccines:_be may_be decrease_be patient's_be response_be vaccine_be"
693,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Killed virus vaccines,int,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be vaccine_be virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be vaccine_be -_be Mitomycin-C:_be may_be cause_be shortness_be breath_be bronchospasm_be -_be Killed_be virus_be vaccines:_be may_be decrease_be patient's_be response_be vaccine_be"
694,Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.,contraceptives,vitamin A,mechanism,Drug_bf Interactions:_bf Women_bf oral_bf DRUG shown_be significant_be increase_be plasma_be vitamin_be A_be levels_be ._be
695,Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.,ascorbic acid,bishydroxycoumarin,mechanism,Limited_bf evidence_bf suggests_bf ascorbic_bf acid_bf may_bf influence_bf intensity_bf duration_bf action_bf OTHER_DRUG ._be
